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In 1992 werkte ik 5 maanden in de research groep van Dr. Charles Rosenfeld en
Dr. Kristine Kamm in het kader van een keuzestage voor mijn doctoraal examen
geneeskunde. Na deze stage nam ik twee besluiten. Ten eerste wilde ik promo-
veren op het onderwerp waar ik in Dallas aan gewerkt had en ten tweede wilde ik
voor langere tijd terug naar de Verenigde Staten. Charles Rosenfeld en Louis
Peeters waren onmiddellijk enthousiast voor dit plan.
Het zoeken naar een promotor binnen de faculteit en het vinden van financiele
steun duurde wat langer. Gelukkig wilden Prof, de Haan en het Termeulen Fonds
mij hier de benodigde middelen voor geven en kon ik beginnen aan dit proef-
schrift.
Vanaf 1995 heb ik met veel plezier in het laboratorium van Charles en Kristine
gewerkt en heb ik ingezien dat promoveren met veel ups en downs gepaard gaat:
van het maar niet willen lukken van experimenten en het ontdooien van een
vriezer met mijn samples tot het winnen van een prijs, the young investigators
award, voor mijn onderzoek in 1998.
Behalve een opleiding tot wetenschapper hebben deze jaren in het buitenland
bijgedragen aan mijn persoonlijke ontwikkeling. Ik heb geleerd om 4000 mijl van
huis mijn eigen boontjes te doppen.
Vervolgens ben ik op mijn plek beland in de genetica, waarin ik sinds 1999
werkzaam ben, mijn proefschrift heb afgerond en nu mijn opleiding tot klinisch
geneticus hoop te voltooien.
Zonder jullie steun was dit me nooit gelukt:
Dr. C.R. Rosenfeld en zijn echtgenote Ann-Marie Rosenfeld, Dr. K.E. Kamm
en Dr. J.T. Stull en de medewerkers van de laboratoria pediatrie en fysiologie in
Dallas.
Prof. dr. J. de Haan en Dr. L.L.H. Peeters van de afdeling gynaecologie in
Maastricht.
Dr. C.T.R.M. Schrander-Stumpel, Dr. C.E.M. de Die-Smulders, Mw. F. van
der Lubbe en overige collegae van de afdeling klinische genetica in Maastricht.
Mijn ouders en zus.
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Smooth muscle contraction
10 CHAPTER I
Morp/70/ogy o/smoo<fc mwsc/e '
Contraction is the primary function of smooth muscle in adult animals. Differen-
tiated smooth muscle expresses a unique assortment of contractile and structural
proteins specialized for their function. Two distinct domains are known: the
cytoskeletal channel and the contractile domain. In contrast to skeletal muscle,
the arrangement of these molecular components still remains unclear. Not only is
the conformation of the contractile unit not completely known, but also its orga-
nization with respect to the cytoskeleton and mechanisms by which the contractile
unit and cytoskeleton are linked remain in debate (1) (Fig 1).
Smooth muscle differs from skeletal muscle and cardiac muscle in that it lacks
visible cross-striations. The contraction unit is similar to the contractile unit of
skeletal muscle, but is not arranged in regular arrays as in skeletal and cardiac
muscle, and therefore, striation is absent. The smooth muscle actins a- and
y-actin, myosin, caldesmon, calmodulin and myosin light chain kinase are local-
ized in the contractile domain, which forms mini-myofibrils responsible for force
development. Actin and myosin are present in the thin and thick filaments, respec-
tively, and slide on each other to produce contraction. The cytoskeleton consists
of p-nonmuscle actin, filamin, calponin and interfilament proteins. Actin is
attached to dense bodies by a-actinin. In fact dense bodies in smooth muscle serve
the same role as Z discs in skeletal muscle. Some of the dense bodies are attached to
the cell membrane, and others are placed inside the cell and are hold together by a
scaffold of structural proteins, which link one dense body to another. Actin and
myosin isoforms differ from the skeletal muscle isoforms. Smooth muscle
contains fewer mitochondria than skeletal muscle and depends to a large extent on
glycolysis for its metabolic needs (1,2,3).
Types
Smooth muscle lines the wall of vessels and hollow organs. There are six types:
vascular, respiratory, urinary, reproductive, gastrointestinal and ocular. In gene-
ral all but ocular smooth muscle consists of unitary smooth muscle, whereas
ocular smooth muscle acts as a multiunit. Unitary smooth muscle consists of a
mass of hundreds of muscle fibers that contract together as a single unit. This
occurs in large sheets or bundles, and their cell membranes adhere at multiple
points as low resistance bridges, so that force can be transmitted from one muscle
fiber to the next. The cell membranes are joined by many gap junctions, through
which ions can flow from one cell to another so action potentials can travel from
one fiber to the next, causing the muscle fibers to contract as one unit. This type of
smooth muscle is referred to as syncytial smooth muscle. Multi unit smooth
muscle consists of individual units without interconnecting bridges (4,5,6).
The physiology and cell biology has been most extensively studied using
vascular smooth muscle (7), whereas smooth muscle biochemistry has been
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Figure 1. Localization of contractile and cytoskeletal components in smooth muscle cells.
studied using gastrointestinal smooth muscle (8). The discussion in this chapter is
confined to the contractile phenotype of differentiated smooth muscle, as smooth
muscle cells in culture rapidly dedifferentiate and change their phenotype to a
noncontractile state (8,9,10).
Excitation-contraction coupling is very slow in smooth muscle compared to skel-
etal or cardiac muscle. Thus less energy is required to sustain a contraction. The
economy of energy utilization by smooth muscle is important, because visceral
organs must sustain tonic contraction for relatively long periods. The membrane
potential in smooth muscle is unstable and shows continuous, irregular contrac-
tions. This state of partial contraction is called tone. The resting value of the
membrane potentials is low when tissue is active and high when inhibited. Smooth
muscle contractions begin 100ms after it is excited. Peak contractions occur at
500ms and decline within 1 or 2 seconds. This is 30 times slower than a contrac-
tion elicited by an average skeletal muscle (11,12).
Smooth muscle is often divided into two types, i.e. phasic and tonic smooth
muscle. Generally, phasic muscles maintain tone poorly, have relatively high
shortening velocities, and are capable of displaying regenerative action potentials.
In contrast, tonic smooth muscles do not display action potentials or regenerative
electrical activity under physiological conditions. They also have slower short-
ening velocities, but can maintain tone more effectively (13,14).
rawsc/e confracftow
In smooth muscle two mechanisms are capable of initiating contraction
responses, i.e., two forms of excitation-contraction coupling exist: pharma-
comechanical and electromechanical coupling. Most smooth muscles contraction
responses are initiated by increases in intracellular calcium. This can be caused by
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nerve or hormonal stimulation, stretch of the muscle fiber, or changes in the chem-
ical environment of the muscle fiber. Smooth muscle, unlike skeletal muscle, does
not contain troponin, which is the regulatory protein that is activated by calcium
ions to cause contraction in skeletal muscle. Instead, an agonist
(pharmacomechanical) binds to a receptor on the smooth muscle membrane and
via G-proteins stimulate IP3 formation, which then releases intracellular calcium
in the cytosol and increases calcium entering the cell (15,16). The membrane can
also be depolarized by KC1 (electromechanical), which also causes calcium to
enter the cell through calcium channels and calcium to be released from intra-
cellular stores. Calcium then binds to calmodulin, which forms a complex with the
enzyme myosin light chain kinase. This catalyzes the phosphorylation of the regu-
latory light chain of myosin via ATP(adenosinetriphosphate) hydrolysis (17,18)
(Fig 2).
The cyclic formation and dissociation of complexes between actin and the
myosin heads leads to a sliding of the thin and the thick filaments. It is caused by
the ATP-ADP cycle in myosin, which produces a directional movement. In resting
muscle the myosin heads are unable to interact with the actin units, because of the
stearic interference by tropomyosin, a regulatory protein (Fig 3).
The hydrolysis products ADP(adenosinediphosphate) and P(phosphate)
remain bound to myosin. When the muscle is stimulated, tropomyosin shifts its
position. The myosin heads can than reach out from the thick filament and attach
to actin on the thin filament. The binding of myosin-ADP and P to actin leads to
the release of the P. The subsequent dissociation of ADP induces a major
conformational change in the myosin head. This change in orientation of the
myosin head relative to actin constitutes muscle contraction. ADP is released at
the end of the contraction. The subsequent binding of ATP to myosin leads to the
rapid release of actin and the myosin head is released from the thin filament.
Finally, the bound ATP is hydrolyzed by the free myosin head, which resets for the
next interaction with actin. When calcium ion concentration falls below a critical
level, the process reverses automatically except for the dephosporylation of
myosin. Reversal of myosin phosphorylation requires the enzyme myosin-
phosphatase, which splits the phosphate from the regulatory light chain. This
causes the cycling to stop and contraction to cease (19,20,21,22).
mwsc/e co«fracfrow
In smooth muscle cells, development of force results from MgATP-dependent
cyclic interaction of myosin in the thick filament and actin in the thin filament. The
force of contraction is regulated by the concentration of free calcium surrounding
the myofilaments (Fig 4). Increases in intracellular calcium result in activation of
calcium/calmodulin (CaM)-dependent myosin light chain kinase (MLCK) and
phosporylation of the 20kDa regulatory light chains (LC). This increases myosin
ATPase activity and cross-bridge cycling. Phosphorylation of LC facilitates the
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Figure 2. Regulation of contraction in smooth muscle.
ability of myosin monomers to assemble into filaments and increases the ATP-ase
activity of myosin at least a 100-fold compared to non-phosphorylated myosin.
Phosphorylation of the LC, together with free calcium are the regulating factors of
the smooth muscle contraction cycle. LC phosphorylation is important for initi-
ating the contraction, since the largest increase in LC phosphorylation occurs in
the first 30-60s when tone is developing. Thereafter, phosphorylation drops to
much lower levels, suggesting that it does not play a role in sustaining a contrac-
tion (23,24,25).
The smooth muscle cell membrane has far more voltage-gated calcium chan-
nels than skeletal muscle cells, but has far less sodium channels. Therefore, the
flow of calcium inside the cell is more important for generating an action poten-
tial. Calcium channels open far more slowly than sodium channels, but remain
open much longer. As noted above, calcium acts directly on the contraction mech-
anism of smooth muscle to cause contraction. Therefore, it is necessary for
intracellular calcium concentrations to be strictly regulated (26).
Smooth muscle intracellular calcium levels increase during contraction as a
consequence of an influx of calcium from the extracellular space, and/or release of
calcium from intracellular stores. Intracellular calcium is stored in the
sarcoplasmic reticulum (SR). Calcium influx across the sarcolemna occurs
through ion channels, or exchangers. Channel-mediated influxes of extracellular
calcium occur through selective calcium-channels or nonselective cation chan-
nels, which can be voltage dependent or independent (27). Release from the
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Figure 3. Schematic diagram showing the interaction of thick and thin filaments in smooth
muscle contraction, (from Steyer biochemistry 4 * ed.)
intracellular stores proceeds through inositol 1,4,5-triphosphate (IP3)-regulated
channels or by calcium-induced calcium release, generally via ryanodine recep-
tor-regulated channels.
Relaxation is established by a decrease in intracellular calcium levels to resting
values. Intracellular free calcium is extruded from the cell by the sarcolemnal
Ca^-ATPase or the NaV Ca^+exchanger. Intracellular calcium can also be taken
up into the intracellular stores by the Ca^-ATPase pump on the SR membrane.
Specific calcium binding molecules are also present both in the myoplasm and in
the SR. They act as cell buffers and are therefore reservoirs of bound calcium
maintaining a low free calcium concentration in the cell and a large capacity of
total calcium in storage.
Once smooth muscle has developed full contraction, the degree of activation can
be reduced to less than the initial levels while the muscle maintains its full force of
contraction. The energy required to maintain a contraction in smooth muscle is
far less than that necessary for skeletal contraction. This mechanism is called the
Latch mechanism. The purpose is to permit a tonic contraction for hours with
minimal use of energy. Furthermore, minimal neurogenic or hormonal stimula-
tion is required (6,19,28). The cycling frequency of the myosin heads and velocity
of contraction are greater when myosin kinase and myosin phosphatase are
strongly activated. If activation of the enzymes decreases through dephos-
phorylation, the cycling frequency decreases, but the myosin heads will remain
attached to the actin filament longer and longer, and the number of myosin heads
attached to actin filaments remains constant. The number of heads attached deter-
mines the static force of contraction. Tension is maintained and energy require-
ment is low, because ATP is not degraded to ADP, unless a myosin head is
detached.
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Figure 4. Proposed mechanism for the generation of
force by the interaction of the myosin unit with the
actin filament. In power stroke, the thin filament moves
relative to the thick filament when the myosin unit
undergoes conformational changes accompanying the
release of ADP. (from Steyer biochemistry 4* ed.) >d.
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Another characteristic of smooth muscle is its ability to return to its original force
of contraction immediately after it has been elongated or shortened. This can be
seen mostly in hollow organs such as, the bladder and uterus, where it is important
to maintain the pressure within the lumen regardless of the length of the muscle
fibers. This mechanism is closely related to the latch mechanism.
Unlike skeletal muscle, which is activated only by nerves, smooth muscle is also
regulated by many hormonal factors. Many circulating hormones are known to
affect smooth muscle contraction. Some are activators of contraction while others
are inhibitors, depending on the receptors on the cell membrane. The most impor-
tant include norepinephrine, epinephrine, acetylcholine, angiotensin II, vaso-
16 CHAPTER 1 O ) J W W
pressin, oxytocin, serotonin, histamine and endothelin. The responsiveness of
smooth muscle to these agonists is tissue specific (29,30).
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Smooth muscle acts to resist an imposed load in the case of large arteries, to propel
organ contents in the case of the bladder and gastrointestinal tract, and to adjust
organ caliber in the case of vascular and airway muscle. Thus, the primary func-
tion of smooth muscle in adult animals is contraction. In fetal sheep the vascular
responses to infusion of several pressor agents, e.g., angiotensin II and a-agonist,
are reported to be less than that observed in the adult ewe (1). For angiotensin II
this may be due to the 10-fold greater metabolic clearance rate in the fetal versus
adult sheep (2,3). However, for other agents similarly studied, the explanation is
less clear. It is possible that differences in vascular reactivity are accounted for by
developmentally - regulated variations in receptor density or subtype and/or asso-
ciated signal transduction mechanisms. Alternatively, the vascular smooth muscle
itself may not be the mature contractile phenotype generally considered necessary
for adult smooth muscle function (4). Proteins associated with smooth muscle
contractile function are developmentally regulated, and the adult isoforms may
not be expressed until late in fetal development or following birth (4,5). However,
there is evidence that the fetal bladder has the capacity to contract, thereby
inducing micturition or voiding quite early in gestation (6,7); but it is not known if
fetal bladder smooth muscle function is similar to or different from that seen in the
adult. It is noteworthy that the smooth muscle cell phenotype(s) expressed in
vascular and nonvascular smooth muscle has not been compared or clearly
defined throughout fetal and neonatal growth and development. Moreover, the
relationship between smooth muscle cell phenotype, protein expression and
contractile function has not been addressed.
Relatively little is known regarding the cellular and molecular function of differ-
entiation of smooth muscle. Cellular differentiation is the process by which
multipotential cells in the developing organism acquire those specific functions
and properties that distinguish them from other cell types. It is widely assumed
that the general principles governing the transition from multi-potential cells to
committed cells (determination), committed cells to a cell-specific phenotype
(differentiation) and the acquisition of the mature phenotype (maturation) will be
applicable to smooth muscle. Maturation refers to the later stages of differentia-
tion and is characterized by acquisition of further cell-specific properties ulti-
mately resulting in the cellular phenotype characteristics of a mature phenotype.
Determination is the process by which multi potential cells in the developing
embryo become committed to a particular cell lineage. These stages represent a
continuum and are only to be distinguished from each other by the cellular
markers that characterize that stage and the molecular processes that control
progression from one stage to another. Differentiation has been most extensively
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studied in skeletal muscle, where studies have shown that maintenance of the
differentiated phenotype involves continuous activation or inactivation of genes
(8,9). For skeletal muscle several groups of regulatory genes have been identified;
however, no such factors have yet been identified for smooth muscle (4). Studies in
other cell types, principally skeletal muscle, have established general principles of
differentiation may be applicable to other cell types, including smooth muscle
(9,10,11). Smooth muscle cells like most cells contain a complete set of genetic
material, but express only a small amount of the genes present. It is not clear what
determines the expression of which genes. In smooth muscle cells the major func-
tion is contraction. On the other hand, smooth muscle cells are capable of a multi-
tude of other functions that vary at different developmental stages, during
vascular repair, and in certain disease states (12). Fully differentiated smooth
muscle cells differentiate at a very low rate, and they produce only small amounts
of extracellular matrix proteins. These processes can be remarkably accelerated
during development, injury or atherogenesis. It is important that during these
stages the smooth muscle cell can maintain its major function, contraction, while
at the same time recruit cells for repair.
Markers o/swoo^ mwsc/e mafwrafrort
Differentiated smooth muscle cells express a unique assortment of contractile and
structural proteins specialized for their contractile function. Two distinct struc-
tural domains have been defined by immunohistochemical techniques (13,14)
(Fig 1).
A cytoskeletal channel and a contractile domain have been described. Myosin
II (conventional filamentous myosin), smooth muscle actins (oc+y), h- and
1-caldesmon, calponin, calmodulin and myosin light chain kinase are co-localized
in the contractile domain, which forms myofibrils responsible for force develop-
ment and/or shortening.
The cytoskeletal channel consists of colocalized P-nonmuscle actin, filamin,
calponin and the intermediate protein desmin; it probably functions to provide
tensile strength for the cell and as a scaffold for a-actin containing dense bodies to
which contractile elements attach. Smooth muscle isoforms of actin, myosin
heavy chain (MHC), caldesmon and calponin are expressed in differentiated
smooth muscle cells (14). The cytoskeletal and contractile proteins of nonmuscle
cells and smooth muscle cells in culture are more plastic in that contractile assem-
blies can form transiently to perform specific functions and then dissemble, as
illustrated by the contractile ring, which is composed of actin and myosin in
dividing cells. Smooth muscle cells in culture express nonmuscle isoforms of the
above proteins (4). However, quantitative and qualitative characterization of the
temporal patterns of expression of smooth muscle and nonmuscle cytoskeletal
proteins in smooth muscle during development is presently lacking.
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Figure 1. Localization of contractile and cytoskeletal components in smooth muscle cells.
As noted earlier, smooth muscle contraction results from the interaction of
myosin in thick filaments with actin in thin filaments, but this may be dependent
upon the expression of adult or mature isoforms of these and other smooth muscle
proteins (4,5). .-.:•.; •••..;- .- ^ •: ; , . . • : . , .
Smooth muscle a-actin was the first known marker of differentiated smooth
muscle cells expressed during vasculogenesis. It is one of six isoactins expressed in
mammalian cells. All are products of separate genes, although they share a high
degree of homology in the protein coding regions. Mature fully differentiated
smooth muscle cells express only four actin isoforms: smooth muscle a-actin,
non-muscle P-actin, non-muscle y-actin and smooth muscle y-actin. The most
abundant of the actin isoforms is smooth muscle a-actin, which accounts for 70%
of actin content. The functional relevance for isoform diversity in actin proteins
might be related to the differential affinity of actin isoforms for actin binding
proteins. However, there are no major functional differences presently known
between the different isoforms, although high smooth muscle a-actin content is
required for high force generating capacity (4,15). Smooth muscle a-actin is not
exclusively expressed by smooth muscle. It is transiently expressed by
mesodermally derived cells during development, tissue repair, and neoplastic
growth.
Expression of isoactins is developmentally regulated in rats and humans.
P-non-muscle actin is gradually replaced by a-smooth muscle actin. There is
marked species variability in degree of expression of these two proteins. In the
newborn rat the predominant actin isoform is P-non-muscle actin, while a-actin
fractional content is approximately 27%. In contrast, a-actin in aortic smooth
muscle cells from the 20 week old human fetus, accounts for 41% of total actin
content (4,16,17).
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The thick filament is an assembly of hundreds of individual myosin II molecules,
each composed of six polypeptide chains, two heavy chains and two pairs of light
chains. The carboxy-terminal ends of two MHC wrap around each other, forming
a coiled-coiled tail involved in filament assembly. The amino-terminal end is
folded in a globular head containing the binding sites for actin and Mg^+-ATP, as
well as for each of the light chains. The head domain is the site of chemo-
mechanical transduction associated with actin-activation of Mg-ATPase activity
(Fig 2). Smooth and nonmuscle myosin II heavy chains are derived from three
distinct genes: one for smooth muscle (SMMHC,18) and two for nonmuscle
(MHC-A and MHC-B,19). The smooth and nonmuscle myosin compose a class
referred to as non-sarcomeric myosins that are distinct from myosins in striated
muscles as they are regulated by Ca-dependent phosphorylation of the regulatory
light chain subunit. Products of all non-sarcomeric MHC genes have been
reported to exist in vertebrate smooth muscle: SMI (204 kDa), SM2 (200 kDa),
MHC-B (200 kDa), MHC-A (196 kDa) (20,21). SMI and SM2 are alternatively
spliced products of the SMMHC gene differing in the carboxyl-terminal portion
of the molecule (20,22) and are considered to be "mature" smooth muscle MHC
isoforms. They account for nearly all MHC found in vascular smooth muscle of
adult animals and humans and are co-expressed in a single smooth muscle cell. An
additional spliced variant of smooth muscle that is not resolved by electrophoretic
mobility occurs by the insertion of 7 amino acids in the Mg^+-ATP binding site
(23). Expression of the non-muscle MHC-A and MHC-B appears to be regulated
in a tissue-dependent manner, with MHC-A expressed most abundantly in spleen
and intestinal cells and MHC-B in brain and testes (24). While there is no evidence
for splice variants of MHC-A, several alternatively spliced isoforms of MHC-B
can occur due to inserts of 10-21 amino acids in the head region. Expression of the
non-muscle isoforms, in particular MHC-B, is observed in smooth muscle cells
undergoing growth and/or cell division and may be representative of cells of the
synthetic phenotype (19,25).
The expression of the various MHC isoforms as well as other contractile and
cytoskeletal proteins appears to be developmentally regulated (5,16,26,27), and
the patterns of expression are both species and tissue specific. Although it is
possible that each of these isoforms may exist within a single smooth muscle cell at
various stages of development, thereby modifying smooth muscle function, this
has not been clearly defined. While the SMI isoform is expressed in varying
amounts in smooth muscle tissues from the fetus and the neonate of several species
(22,26,27,28), including the human, the expression of SM2 is quite variable, and
it is unclear when in development it is first present. For example, SM2 mRNA and
protein are not detectable in fetal aorta and barely detectable in the neonate, but
are seen in the human fetal rabbit aorta as early as 14 to 31 weeks gestation, with
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Figure 2. Schematic diagram of a myosin molecule.
values increasing after birth (26,27). Further studies in a single species are needed
in order to clarify this issue.
MHC-B, which also has been referred to as bovine brain MHC, chicken
fibroblast MHC and SM embryonic (Smemb), is expressed most predominantly in
rabbit and human fetal aorta and decreases after birth (22,27). It is also found
transiently in proliferating smooth muscle cells within arteriosclerotic neo-
intimas and cultured vascular smooth muscle cells (19,22). During development
MHC-B expression is reported to decrease, and in human tissues it is associated
with a disappearance of MHC-B mRNA by adulthood (27). The fall in MHC-B
expression is associated with increasing amounts of SM2 protein and mRNA after
birth, suggesting that this switch may serve as a marker for smooth muscle matu-
ration. What orchestrates these synchronous changes in protein expression within
the smooth muscle cell is not known. It has been observed that aortic smooth
muscle MHC-B expression falls during development, and this is associated with a
rise in SM2. In contrast, MHC-B was not expressed in ovine fetal bladder smooth
muscle during the same period of development. If the repression of MHC-B
expression is a marker of smooth muscle maturation, this suggests that bladder
smooth muscle is more mature than vascular smooth muscle at similar times in
development.
MHC-A was initially identified in human platelets and subsequently in aortic
smooth muscle from neonatal rats and the bovine fetus (28). It was reported to
decrease with increasing age. Its presence in the fetal rabbit aorta, however,
remains questionable (22). While existing studies have provided insight into the
ontogeny of MHC isoform expression in smooth muscle, they are limited by large
gaps in time between tissue samples, the study of relative few tissue samples at
each time period of development, and in general, little or no parallel data
regarding the tissue contents of these proteins. Moreover, previous studies have
provided no information regarding the impact of expression of these various
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isoforms, and in particular MHC-B, on smooth muscle function during develop-
ment. • • . ••• . •.' .'.:'.• i'-.n.j-S-i sJini'.'•;?*"??( ;sr*i ^
Although there is substantial homology between MHC-B and both SMI and
SM2, the function of MHC-B appears to be different. As noted earlier, it is found
in cultured vascular smooth muscle cells and transiently in proliferating smooth
muscle cells in damaged intimas (22). Thus, it may be integrated in smooth muscle
proliferation, growth or migration. In support of this, antisense nonmuscle MHC
oligonucleotides have been reported to suppress smooth muscle proliferation in
vitro (19). There also is a phenotypic change in proliferating smooth muscle cells
in culture, which express the MHC-B isoform, from spindle-shaped cells capable
of contraction to polygonal cells with an increased amount of subcellular
organelles involved with protein synthesis. These cells lose their thick filaments
and have decreased capacity to contract, which may be proportionate to the
expression of nonmuscle MHC (29). Therefore, the expression of MHC-B may
constitute a marker for the synthetic state of smooth muscle cells, and its suppres-
sion during development may signal maturation of smooth muscle cell function.
Studies defining the regulation of non-sarcomeric MHC gene expression are in
their early stages. The promotor and flanking region of the SMMHC (18) and
MHC-A, but not the MHC-B gene have been cloned, sequenced and analyzed.
While the 5'-flanking region of the SMMHC contains a canonical TATA box
sequence, MHC-A does not, which is typical of a housekeeping gene (18). Further
analysis of the SMMHC promotor and flanking regions will continue with the aim
of defining transcriptional activation factors that may yield insight into the regu-
lation of differentiation of smooth muscle (18). Studies of the MHC-B gene
promotor and flanking regions will provide novel insights into smooth muscle
differentiation by revealing repressors of nonmuscle genes • • •.
Caldesmon and calponin are thin-filament binding proteins found in smooth
muscle cells that have been attributed a role in modulating the interaction of actin
and myosin.
Caldesmon is considered a part of the contractile domain and is a major
calmodulin- and actin-binding protein in smooth muscle and non-muscle cells
(30). It inhibits superprecipitation and actomyosin Mg^+ATP-ase activity (31).
When added to permeabilized smooth muscle, it causes relaxation (30,31). Two
isoforms exist: h-caldesmon a 150 kDa protein and 1-caldesmon a 70 kDa protein.
They are derived from a single gene by alternative splicing. (30,32). h-Caldesmon
is abundantly expressed in differentiated smooth muscle, whereas 1-caldesmon is
predominantly expressed in non-muscle and immature smooth muscle cells
(30,33). Neither isoform is detectable in adult skeletal or cardiac muscle. Expres-
sion of caldesmon is developmentally regulated (34). 1-Caldesmon is detected in
chicken gizzards at 10 days of gestation, while h-caldesmon is first expressed
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between 10 and 13 days. From day 13 there is a progressive increase in
h-caldesmon, that parallels increases in desmin, myosin and p-tropomyosin. In
contrast, 1-caldesmon decreases progressively to undetectable levels 3 days
posthatching (33).
Calponin is an actin-binding protein, which interacts with actin and
tropomyosin in a Ca^-dependent manner and with calmodulin in a Ca^-inde-
pendent manner. It inhibits the Mg^+-ATPase activity of myosin and therefore
regulates smooth muscle contraction (35); but the mechanism remains unclear.
Calponin is expressed in both the contractile and the cytoskeletal domain, but is
predominantly located in the cytoskeletal compartment (14), where it is localized
in the cytoplasmic dense bodies and the adhesion plaques at the cell surface.
Calponin like caldesmon is not unique to smooth muscle cells.
H //g/rt <:/?#/« JEsmase and Myosm
Myosin light chain kinase (MLCK) is activated by calcium and calmodulin and
catalyzes the transfer of phosphate from MgATP to a serine residue near the
N-terminal of the myosin regulatory light chain. Phosphorylation is more impor-
tant for regulation in smooth muscle compared to skeletal muscle.
Phosphorylation of the regulatory light chain results in a marked increase in
actin-activated myosin ATPase activity (36). There are two primary forms of
MLCK; smooth muscle and skeletal, which are derived from two distinct gene
products. The smooth muscle isoform is also present in nonmuscle cells.
Besides the two heavy chains, the myosin molecule consists of two pairs of
light chains: the essential 17 kDa light chains and the 20 kDa regulatory light
chains. Two smooth muscle isoforms of the essential 17 kDa light chain have been
identified (37,38). They are derived from the same gene and are the products of
alternative splicing (39,40). LC17a is the most acidic one and LC17b the more
basic (37,38). Gastrointestinal smooth muscle and fibroblasts predominantly
expresses the LCI7a form, while vascular smooth muscle expresses both. The 17
kDa light chains are necessary for modulating the affinity of myosin for actin and
actomyosin ATPase activity. The ratio of the 17 kDa isoforms might affect the
functional and enzymatic activity. Tissues high in LCI7b have a lower actomy-
osin ATPase activity compared to those with more abundant LCI7a (37).
Multiple isoforms of the regulatory 20 kDa myosin light chain exist. LC20a is
a smooth muscle light chain, whereas LC20b is a nonmuscle isoform, although
both are expressed in smooth muscle and nonmuscle. It is not known if the
different isoforms have different functional effects.
Desmtn
The cytoskeleton of smooth muscle contains structural filaments of the interme-
diate class (lOnm), that are composed primarily of desmin and vimentin, with
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desmin being a muscle specific form. However, the relative portion differs
between smooth muscle tissues. The function of the intermediate filaments (IF)
remains unclear, although they are thought to constitute a part of the cellular skel-
eton in smooth muscle (41). Desmin is developmentally regulated in skeletal and
cardiac muscle (42,43,44). There is, however, a relative paucity of information
regarding developmental regulation of desmin in vascular and visceral smooth
muscle. It is expressed in developing smooth muscle from gastrointestinal and
urogenital tracts (42,43), but does not appear to be expressed in the developing
vasculature of the mouse (45).
According to structural data, filamin is considered to be associated with the
intermediate filaments and actin (46). It is a 280 kDa protein, which dimerizes at
the extreme c-terminal of the protein. The function of filamin in the cell is pres-
ently unknown. The contractile function might be less clear regarding its associa-
tion with the structural proteins. Filamin has shown to inhibit actomyosin-
phosphatase in vitro at low concentrations and potentiate it in high concentra-
tions.
CONCLUSION ., . v . ,,, ;. , , ; , ,„. , . , ; . , ;
Substantial studies have been performed in intact fetal animals, and in particular
in fetal sheep over the past 20 years. These studies have been performed to deter-
mine the ability of the fetal cardiovascular system to adapt to various stress states,
e.g, severe hypoxemia or hypovolemic shock as might occur during acute
fetal-maternal hemorrhage. Still, our understanding of the development and the
function of fetal smooth muscle remained cursory. What regulates smooth muscle
growth and differentiation during development? The proteins that govern smooth
muscle contractility are developmentally regulated and tissue specific. For
example fetal bladder, which is mature very early in gestation, and aorta, which
becomes mature predominantly after birth. The studies described in this thesis
will provide a detailed characterization of the ontogeny of expression of both the
smooth muscle contractile and cytoskeletal proteins, and importantly the relation
that exists between these proteins and smooth muscle function. The potential
impact rests not only in understanding smooth muscle development and what
orchestrates these alterations, but also in understanding how smooth muscle
growth is regulated, thereby potentially impacting this knowledge about smooth
muscle responses to various insults as well as repair.
The aim of this project is to examine the proteins associated with smooth muscle
function and proliferation during development and pregnancy, the specific goals
of this project are to:
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1. Complete the descriptive studies of the expression of smooth muscle and
non-muscle MHC isoforms in ovine fetal and neonatal bladder and vascular
smooth muscle;
2. Compare ontogeny of the expression of contractile proteins with organ
function by measuring stress generating capacity of bladder and vascular
smooth muscle; u v :.
3. Determine if differences in vascular smooth muscle protein expression exist
between umbilical and systemic arteries and if these differences are associ-
ated with different capacities to generate stress;
4. Characterize the contractile protein expression in myometrium of fetal and
postnatal sheep and describe the effect that having been pregnant has on the
* expression of contractile proteins; and
5. Examine the hypothesis that cytoskeletal proteins are expressed in coordina-
tion with actin during development in aortic and bladder smooth muscle.
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During ovine development there are substantial tissue specific alterations that
occur in the expression and contents of several important contractile proteins and
the nonmuscle MHC isoforms in smooth muscle of a number of arteries and
visceral tissues. In this thesis we studied animals before 80 days of gestation and
after 3 mon postnatally, which had not been done before. We studied in detail the
smooth muscle proteins associated with the development of smooth muscle
cytoskeleton, e.g. a-actin, desmin, filamin and calponin. Furthermore, the expres-
sion of other contractile protein has been extensively studied. They play an impor-
tant role in the contractile properties of smooth muscle cells and possibly their
maturation, e.g. caldesmon, a-actin, myosin, calponin, calmodulin, and myosin
light chain kinase.
Tissue
Female fetal (72-140d of gestation, n=19; term 145d), postnatal sheep (ld-3mo,
n=21) and maternal sheep (n=4-6) were euthanized by rapid intravenous injection
of pentobarbital sodium (50mg/kg) to the mother or neonate via the external
jugular vein. Segments of abdominal aorta, bladder and myometrium were
quickly obtained from fetal, postnatal and adult animals and placed into iced
physiological buffed solution containing (in mm): 137.0 NaCl, 2.7 KC1, 10
Na2HPO4, 1.76 KH2PO4. 0.1% diethyl pyrocarbonate, pH 7.4. Adventitia and
epithelium from the myometrium were removed with sharp dissection and a soft
cotton swab. Strips of tissue were cut, blotted dry to remove of excess water and
capillary blood, frozen in liquid nitrogen, and stored at -80°C until studied. Addi-
tional segments were obtained in order to measure stresses. These studies were
approved by the Institutional Review Board for Animal Research.
Female near-term fetal sheep (n=12; 130-145 days of gestation, term 145+5
days) and maternal sheep (n=8) were killed by rapid intravenous injection of
pentobarbital sodium (50 mg/kg) to the mother via the external jugular vein.
Segments of abdominal aorta, femoral artery and external and internal umbilical
artery in case of the fetus were removed from each animal and placed into iced
physiologic buffered solution (137.0 mM NaCl, 2.7mM KC1,10 mM Na2HPO4,
1.76 KH2PO4, 0.1% diethyl pyrocarbonate, pH 7.4). Endothelium and
adventitia were removed from the arteries by sharp dissection. Strips of tissue
were cut, blotted dry to remove excess water and capillary blood, frozen in liquid
nitrogen, and stored at -80°C until studied.
T;s5«e preptf ration rw wode/ o^pw/wonary /^ ypertews/oM
Eight pregnant mixed-breed western ewes with twin gestations were operated
upon at the University of California, San Francisco at ~140d of gestation under
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sterile condition with epidural anesthesia and intravenous sedation. One twin
fetus (n=8) was partially exposed through a hysterotomy, and a thoracotomy was
performed as previously described (6). Briefly, the arterial truck and the main
pulmonary artery were dissected, and an aortotomy and pulmonary arteriotomy
were performed. Between these two arteries, an 8.0-mm expanded polytetra-
fluoroethylene vascular graft (2 mm length) (Gore-tex; W.L. Gore and Assoc) was
placed to provide an aortopulmonary shunt. The other twin (n=7) served as a
control and was not operated upon. The thoracotomy incision was closed, and the
fetus was returned into the uterus. Amniotic fluid was replaced by warm saline
before closure of the uterine incision. Postoperative, the ewes recovered and the
fetuses were allowed to deliver spontaneously at term. Following delivery, lambs
were maintained in a holding area until one month of age when they were killed
with lethal doses of intravenous pentobarbital sodium, and tissue was collected.
These protocols were approved by the Committee on Animal Research of the
University of California, San Francisco.
The lungs were removed in block and third and fourth generations of PA and
femoral arteries were collected. Adventitia and adjacent lung tissue were removed
by blunt dissection and endothelium was removed with a soft cotton swab. Strips
of arteries were cut, frozen in liquid nitrogen, and stored at -80°c until studied.
Sodium dodecyl sulfate (SDS) homogenates were prepared from 10-20mg
samples of frozen tissue as previously reported. Briefly, homogenates were
divided into two aliquots. One was subjected to centrifugation at 10,000 x g for 2
min and the supernatant removed to determine the soluble or cellular protein in
each sample. The other sample was not centrifuged and was used to determine the
total homogenate protein. Aliquots of both samples were analyzed for protein
content by BCA reagent (Pierce, Rockford, III.). Aliquots of the supernatant
containing bromphenol blue and 2-mercaptoethanol were subjected to SDS-Page,
using 3-20% and 4% polyacrylamide gels to determine the contents of total actin,
MHC and MHC-isoforms. For each tissue mini-gels were loaded with 20-40ug of
soluble protein and subjected to electrophoresis at 200V until the dye front
reached the bottom of the gel. Gels were stained with Coomassie Brilliant Blue
overnight and appropriately destained to remove background staining. Stained
gels were scanned, each lane in duplicate, with a laser densitometer (LKB Instru-
ments, Inc., Stockholm, Sweden) to estimate the relative amounts of actin, MHC.
Differences between measurements were <5%, and values for each band were
averaged. The fraction of stained protein accounted for by actin, MHC was
converted to micrograms using the total protein quantified by BCA reagent in
each sample. Values are expressed as (ig/mg of wet weight. The band corre-
sponding to filamin was previously identified by immunoblotting. Interfilament
proteins in smooth muscle can be estimated from whole muscle preparations
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owing to their relative abundance. In addition, we confirmed by immunoblotting
that this band contained desmin in both aortic and bladder samples. Values for
each band were averaged, and the fractional content of filamin or IF protein was
converted to micrograms using the total protein quantified by BCA reagent.
Values are expressed as ug/mg of wet weight.
MHC: Tissue extracts were subjected to electrophoresis in 4% polyacrylamide
gels. Proteins were electrophoretically transferred to nitrocellulose paper at 80
mA overnight. Blots were incubated overnight with an antibody against SM2
(1:4000) or MHC-B (1:20,000). Following 2h incubation with goat anti-mouse
IgG conjugated with horseradish peroxidase (1:15,000), immunoreactive protein
was visualized by chemiluminescence (ECL Amersham).
Caldesmon and calponin: Tissue extracts (2.5ug of soluble protein) were
subjected to electrophoresis in 3-20% gradient polyacrylamide gels. Proteins
were electrophoretically transferred to nitrocellulose paper at 100V for lh. The
membranes were cut according to molecular weight markers. The top half of these
blots were incubated overnight with antiserum against caldesmon (1:10,000),
which detects the h- and the 1-form of caldesmon, and with goat anti-rabbit IgG
conjugated with horseradish peroxidase (1:15,000). Immunoreactive protein was
visualized by enhanced chemiluminescence (ECL, Amersham). The bottom half
of the membranes were incubated overnight with an antibody against calponin
(1:10,000). The next day they were incubated with goat anti-mouse IgG conju-
gated with horseradish peroxidase (1:15,000) and were visualized by ECL.
MLCK: Tissue extracts (5|ig of soluble protein) were subjected to electropho-
resis in 5% polyacrylamide gels. Proteins were electrophoretically transferred to
nitrocellulose paper at 100V for lh. Blots were incubated overnight with an anti-
body against myosin light chain kinase (1:7500). The next day they were incu-
bated with goat anti-mouse IgG conjugated with horseradish peroxidase (1:3000)
and were visualized by enhanced chemiluminescence (ECL, Amersham).
MLC: These same samples (15ug of soluble protein) were loaded and sepa-
rated on 15% polyacrylamide gels. Proteins were transferred to 0.2um
nitrocellulose paper at 100V for lh. The membranes were incubated overnight
with antiserum against the regulatory light chain (1:5000) and with goat
anti-rabbit IgG conjugated with horseradish peroxidase (1:15,000) and visual-
ized by ECL.
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Strips of aorta and bladder were mounted for measurement of isometric force and
quick-frozen with tongs precooled in liquid nitrogen either at rest or at the time of
maximum contraction, using 10"^  M phenylephrine for the aorta and femoral
MATERIALS AND METHODS 37
artery, 10"^  M carbachol for the bladder and 10"^  M seretonin for the umbilical
artery. The frozen muscle was weighed, placed in frozen slurry of trichloroacetic
acid (10%, wt/vol) in acetone that contained DTT (lOmM), and allowed to thaw
in order to denature cellular proteins. Thereafter the muscle was placed in 60 vol
of trichloroacetic acid (10%, wt,vol) and DTT (lOmM) and homogenized. The
precipitated protein was washed with diethyl ether and then suspended in
urea-glycerol buffer for electrophoretic analysis of light chain phosphorylation by
immunoblotting (24,27). Samples were subjected to electrophoresis for lh at
400V in a gel containing 10% polyacrylamide and 40% (vol/vol) glycerol. Protein
was transferred to nitrocellulose paper and nonphosphorylated and
phosphorylated forms of the light chain (1:10,000) and peroxidase-conjugated
goat anti-rabbit IgG (1:15,000) with ECL. Relative amounts of nonphos-
phorylated light chain were quantified by laser densitometry.
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Tissues were quickly placed in physiologic saline solution (PSS) containing (in
mM) 120.5 NaCl, 4.8 KC1, 1.2 MgSC>4, 1.2 NaH2SO4, 20.4 NaHCO3, 1.6
CaCl2, 10 dextrose and 1 pyruvate. The endothelium was dissected away and
strips of equal width were cut with a double blade cutting-tool in the circular
direction of the muscle.
The strips were tied at both ends with 6.0 silk; the bottom was hooked to a
stainless steel rod attached to a calibrated mechanical drive to adjust muscle
length and the top part was tied to a Grass FT.03C force transducer. Force was
recorded on a Grass model 7D polygraph. The strips were suspended in a 25-ml
jacket-organbath containing PSS at 37 C and bubbled with 95% C>2-5% CO2 to
maintain a pH of 7.4. Length-force relationships were determined as follows.
Each strip was stretched to 0.5g initially and length was measured; this was
followed by equilibration for lh. The PSS was emptied from each bath and
replaced with 65mM KC1 (KC1 isotonically replaced NaCl in PSS). Maximal force
obtained in response to KC1 depolarization at a given length was taken as the total
force. Passive force contributed by connective tissue in the strip was obtained after
the tissue was placed in calcium-free PSS containing 2 mM ethylene
glycol-bis(-aminoethylether)-N,N,N',N'-tetraacetic acid, eliminating force
contributed by contraction of smooth muscle cells. After obtaining a value for
passive force, calcium-free PSS was removed and replaced with regular Ca^-con-
taining PSS. Normal spontaneous activity was allowed to return, the tissue was
stretched to a new length, and the stimulation-relaxation protocol was repeated.
Active force generated by the arteries was obtained by subtracting the passive
from total force at the respective length. The length at which maximal active force
(FQ) occurred was defined as the optimal length (LQ) for each muscle strip. After
this procedure, tissues were blotted and weighted. Tissue cross-sectional area was
calculated based on the weight, density, and length of the tissue at LQ. Stress
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(N/m^) was calculated by dividing the active force at optimal length by the
cross-sectional area.
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Strips of internal and external umbilical arteries were cut and hang in the muscle
bath as for the optimal length-tension measurements. The strips were stretched to
their optimal length as determined by length-force calculations, within three
stretches of 20 minutes each. The strips were then stimulated twice with 65mM
KCL. All strips were relaxed with Ca^+-free PSS after each contraction. The strips
of external and internal umbilical arteries were subsequently stimulated with
phenylephrine 10'^ M, histamine 10"^M, serotonin 10"^M, carbachol 10'^M,
bradykinin 10'^M, PGF2 10"*M, PGE2 10^M, angiotensin II lO^M, endothelin
10'*M. Concentration of agonist was determined by the maximal contraction
given by a certain concentration of agonist in human umbilical cords.
STATISTICS
Data was analyzed using polynomial regression analysis to obtain estimates for
significance of fit to functions indicating non-zero slope (Sigma Stat 1.0). Signifi-
cance between groups was determined by Student's t-test and one-way analysis of
variance (ANOVA) with Newman-Keuls correction for multiple comparisons.
Grouped data are reported as means ± SEM. Significance was taken as p<0.05. In
addition animals were divided in 7 groups in the first study: fetal at <100d,
101-130d, and 131-145d gestation; postnatal at l-7d, 8-21d, 22-30d, and >85d
after birth.
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ABSTRACT
Maturation rates of vascular and visceral smooth muscle during ovine develop-
ment were compared by quantifying contractile protein, myosin heavy chain
(MHC) isoform contents and contractile properties in aorta and bladder from
female fetal (n=19) and postnatal (n=21) sheep. Actin, myosin, and protein
contents rose progressively throughout development in both tissues (p<0.003);
however, expression patterns differed. During the last trimester, ».e. 101-130d
(term -145d), bladder actin and MHC contents were ~2-fold greater (p<0.04)
than those in aorta. While the fractional content of 204kDa smooth muscle
MHC (SMI) in bladder decreased from 74±3% at midgestation to 48±2%
3mon postnatal, aorta exhibited an increase from 30±2% to 65±2%. Bladder
MHC migrating at 200kDa contained only smooth muscle SM2 throughout
development. In contrast, 200kDa MHC in aorta was predominantly non-
muscle MHC-B at mid-gestation, which was gradually replaced by SM2 as
development progressed. Along with its early expression of SM2, bladder
muscle obtained maximal stress generating capacity (1.7 x 10^ N/m^) by term
gestation, whereas aorta exhibited no contractions until after birth. We
conclude that whereas aortic smooth muscle maturation is delayed until after
birth, bladder smooth muscle matures biochemically and functionally during
prenatal development, thus supporting early requirements for micturition.
Index terms: Actin, myosin, aorta, bladder
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Rapid growth and maturation of the smooth muscle-containing organ systems are
hallmarks of fetal development. Internal organs are formed in the mid to late
stages of embryogenesis, with differentiation-specific smooth muscle protein
markers seen first in the vascular outflow tract, followed by bronchial buds, gut,
peripheral vasculature and bladder (1). Subsequent increases in contractile
protein content, as well as muscle-specific composition, during fetal and postnatal
development should accompany the need for increasing contractile capacity
during maturation brought about by growing demands for organ function. In
support of this, we found that, within the vasculature of near-term fetal sheep,
umbilical arteries were both biochemically and functionally comparable to
systemic vessels from adults, whereas fetal systemic vessels exhibited an immature
phenotype (2) consistent with the relatively minor contribution of the systemic
circulation as compared to the umbilical circulation to alterations in fetal vascular
resistance (3,4). Likewise in a preliminary study comparing protein composition
of visceral and vascular smooth muscles from late fetal gestation and neonatal
male sheep (5), we noted that the bladder expressed only smooth muscle isoforms
of myosin heavy chain (MHC), whereas the aorta expressed both smooth and
non-muscle isoforms, suggesting that among organ systems there may also be
differential rates of smooth muscle maturation.
Smooth muscle differentiation and maturation are distinguished by the
gradual and sequential induction of tissue-specific protein markers (reviewed in
Owens, 1995) (6). Smooth muscle myosin heavy chain (SM-MHC) is a key
marker of the differentiated phenotype in that it appears exclusively in the smooth
muscle cell lineage during development (1). Mature, "contractile" smooth
muscles express smooth muscle and to a minor extent non-muscle isoforms of
MHC (6,7). The four SM-MHC isoforms arise from a single gene through alterna-
tive splicing (reviewed in Kelley and Adelstein, 1994) (8). SMI (204 kDa) and
SM2 (200 kDa) differ in their carboxyl-terminal tail region, and additional splice
variants of these forms contain a small insert in the amino-terminal head region.
Non-muscle MHC isoforms MHC-A (196 kDa) and MHC-B (200 kDa) are the
products of two distinct genes (9). They are expressed in all cell types and impli-
cated in actin-based motile functions such as cytokinesis and cellular locomotion
(10). Developmental patterns of MHC isoform expression in smooth muscle are
largely understood from studies of blood vessels and exemplified by the presence
of SMI and non-muscle MHC in the late gestation fetus and neonate, with a
gradual onset of SM2 expression after birth accompanied by reciprocal declines in
non-muscle MHC (6). Expression patterns of MHC markers have been evaluated
as qualitative assessments of differentiation; however, functionally consequential
quantitative increases in content of these with maturation have received limited
attention.
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In the present study we further investigate the proposal that smooth muscle matu-
ration parallels requirements for organ function. Amounts and patterns of actin
and MHC isoform expression as well as stress generating capacity were compared
between the bladder, a visceral tissue known to be active in fetal sheep (11,12),
and the aorta, a vascular smooth muscle tissue extensively described in other
species (13,14,15,16,17,18) and known to be less reactive in fetal than adult sheep
(2,4). The sheep offers certain advantages as a model for studying aspects of fetal
physiology, owing to the experimental ability to modify the hormonal milieu
while studying physiologic responses i« two (19,20,21). Moreover, significant
quantities of smooth muscle tissues can be obtained from fetal and neonatal sheep
to perform protein analysis and contractile measures, thus providing a model
system for relating contractile protein phenotype to contractile function over
extended periods of development. The present results indicate that bladder
smooth muscle undergoes accelerated maturation of contractile protein pheno-
type accompanied by the early onset of force development, as compared to the
vascular smooth muscle of the aorta. :
METHODS
T/sswe
Female fetal (72-140d of gestation, n=19; term ~145d) and postnatal (l-120d,
n=25) sheep were euthanized by a bolus infusion of sodium pentobarbital i/ia the
external jugular vein (50 mg/kg) of the mother in case of the fetus or of the
newborn. Segments of abdominal aorta and the entire bladder were quickly
removed and placed into iced phosphate buffered saline (137.0 mM NaCl, 2.7
mM KC1, 10 mM Na2HPC>4, 1.76 KH2PO4, 0.1% diethyl pyrocarbonate, pH
7.4), which was bubbled with oxygen. Tissues for contraction measures were
transported within 30min to another laboratory and transferred to oxygenated
physiological salt solution (22) for dissection as described below. Endothelium
and adventitia were removed from the aorta with a soft cotton swab and blunt
dissection, respectively, and the epithelium was removed from the bladder by
sharp dissection. Strips of tissue were cut, blotted dry to remove excess fluid and
capillary blood, frozen in liquid nitrogen, and stored at -60°C until studied. Some
strips were reserved unfrozen for measurements of isometric force.
Samples of frozen tisue (10-20 mg) were homogenized in 40 volumes of sodium
dodecyl sulfate (SDS) buffer containing 2% SDS, 20 % sucrose and 0.4M Tris (pH
6.8) (22,5,23). The homogenates were divided into two aliquots. The first was
used to determine the total homogenate protein content. The second was
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subjected to centrifugation at 10,000 x g for 2min, and the supernatant was
removed in order to determine the soluble or cellular protein in each sample.
Densitometric analysis of supernatant and pellet fractions subjected to SDS-
polyacrylamide gel electrophoresis (PAGE) showed that >90% of myosin and
>85% of actin were recovered in the supernatant. Aliquots were analyzed for
protein content by BCA reagent (Pierce). To the remaining homogenate and
supernatant samples were added 2-mercaptoethanol and bromophenol blue to
achieve final concentrations of 5% and 0.04% respectively. Samples of soluble
protein [20-40 ng based on loading curves determined for each tissue type (22)]
were then subjected to PAGE in 3-20% and 4% polyacrylamide gels to determine
the contents of actin and MHC and the relative amounts of MHC isoforms,
respectively. Gels contained molecular mass standards used to confirm relative
mobility (Bio-Rad Laboratories). Positive identification of the positions of MHC
and actin bands was confrimed by western blotting with antibodies generated in
this laboratory (smooth muscle MHC) and purchased from Sigma (a-actin). The
fractions of Coomassie blue-stained protein accounted for by actin and MHC in
3-20% gels and MHC isoforms in 4% gels were estimated by scanning laser
densitometry to obtain a profile of peaks followed by area integration of the
absorbency signal for each peak (Model 2202/2220, LKB Instruments). Lanes
were scanned in duplicate. The fraction of protein accounted for by actin and
MHC was converted to micrograms knowing the amount of protein loaded.
Values are expressed as |ig/mg of wet weight.
Westerw
Tissue extracts were subjected to electrophoresis in 4% polyacrylamide gels, and
proteins were electrophoretically transferred to nitrocellulose paper at 80 mA
overnight. Blots were incubated overnight with antiserum. Antisera to SM2
(1:4000) or MHC-B (1:20,000) were raised in this laboratory against synthetic
peptides specific to each form and characterized as described previously (5). Anti-
sera against MHC-A (1:20,000) were generously provided by Drs. N. Murakami
and J.R. Sellers. Purified bovine brain MHC-B was the gift of Dr. Barbara
Barylko. Antibodies to MLCK (1:3000) were raised in this laboratory against
purified bovine tracheal smooth muscle MLCK. Following 2h incubation with
goat anti-rabbit IgG conjugated with horseradish peroxidase (1:15,000), immu-
noreactive protein was visualized by chemiluminescence (ECL Amersham).
Muscle strips (1.4 mm wide) from aorta and bladder were prepared using a
double-bladed cutting tool (22,24). Strips of aorta were open rings with endothe-
lium removed by gently rolling a moist cotton swab over the lumenal surface.
Bladder strips were cut from muscle in the longitudinal orientation and dissected
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clean as described above. Strips were mounted in organ baths for measurement of
isometric force no more than two hours after being removed from the animals.
Baths contained oxygenated (95% O2,5% CO2) physiological salt solution (PSS)
[120.5 mM NaCl, 4.8 mM KC1, 1.2 raM MgCl2, 1.6 mM CaCl2, 1.2 mM
NaH2PO4,20.4 mM NaHCO3,10 mM dextrose, 1 mM pyruvate, pH 7.4,37°C]
(22). Length-force relations were determined for each tissue type at each gesta-
tional age. Stresses in response to phenylephrine (10'^ M) or PSS containing 65
mM KC1 (replacing NaCl) were determined in strips stretched to the optimal
length (LQ) for maximal force (F<>). Tissue cross-sectional area was calculated
based on weight, density, and length of the tissue at LQ. Stress (N/m^) was calcu-
lated by dividing active force at L<, by the cross-sectional area (25,26).
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The ability of contractile proteins to be activated by myosin light chain
phosphorylation was assesed by comparing values in strips relaxed in calcum-free
buffer with those maximally activated. Strips of aorta and bladder mounted for
measurement of isometric force were quick frozen with tongs precooled in liquid
nitrogen either relaxed or at the time of maximum contraction, using 10~-* M
phenylephrine for the aorta or 10"^  M carbachol for the bladder. The frozen
muscle was weighed, placed in a frozen slurry of trichloroacetic acid (10%,
wt/vol) in acetone that contained DTT (lOmM) and allowed to thaw. Following a
lOmin incubation the liquid was decanted and the strip was homogenized in 60
volumes of trichloroacetic acid (10%, wt/vol) and DTT (lOmM). Precipitated
protein was washed with diethyl ether and then suspended in urea-glycerol buffer
for electophoretic analysis of regulatory light chain phosphorylation by
immunoblotting with antiserum raised against light chain purified from bovine
tracheal smooth muscle (27). Separated proteins were transferred to
nitrocellulose paper and light chain was detected by immunoblotting with specific
antibodies using the ECL detection system (Amersham). Relative amounts of
nonphosphorylated and phosphorylated light chain were quantified by scanning
laser densitometry.
STATISTICS
Data were analyzed using polynomial regression analysis to obtain estimates for
significance of fit to functions indicating non-zero slope (Sigma Stat 1.0). The vari-
ables used were protein contents (y-axis) versus gestational age in days (x-axis).
This type of analysis is particularly useful when changes over time are gradual and
not detected by analysis of variance of grouped samples. In addition, animals were
divided into 8 groups. Fetal stages represent 1) midgestation (<100d), 2) the
period of rapid growth preceding increases in estrogen and cortisol (101-130d),
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and 3) preparation for parturition (131-145d gestation). Postnatal stages repre-
sent 1) adaptation immediately following birth (l-7d), 2) intermediate postnatal
adaptation (8-21d), 3) completion of postnatal adaptation (22-30d), 4) 3-4mon
or late postnatal, and 5) adult (> lyr). Significance between groups was deter-
mined by one-way analysis of variance (ANOVA) with Newman-Keuls correc-
tion for multiple comparisons. Grouped data are reported as means ± SEM.
RESULTS .
Protem Contents
In both aorta and bladder, total and soluble protein contents increased during
development. Regression analysis in aortic smooth muscle demonstrated gradual
increases from <100d gestation to >3mon after birth (R=0.40 and 0.48; p=0.007
and 0.001, respectively; first order). Because of the gradual nature of these
increases, significant differences between agegroups were detected only at 3
months after birth (Table 1). In contrast, bladder smooth muscle total and soluble
protein increased around the time of birth, as evidenced by highly significant poly-
nomial regressions (R=0.62 and 0.83; p<0.001 each; second order) and
pronounced differences occurring after 130d gestation (total) or 7d postnatal
(soluble;Table 1). Additional but modest increases in soluble protein occurred
after week one postnatal (Table 1).
Differences between tissues were also observed. Prior to 1 OOd gestation aortic
total protein exceeded that of bladder (p<0.02, ANOVA), whereas after that age
values did not differ. In contrast, soluble protein contents were similar at <100d
gestation, but after that, bladder contents always exceeded aorta (p<0.03,
ANOVA).
Acrr'w a«rf Myos»« Hetff;y C/?(3/« Contents
Actin and MHC contents in aortic smooth muscle also increased during develop-
ment (Fig 1). Actin contents rose abruptly after 1 OOd gestation (Fig 1), increasing
-75%, and then rose gradually, resulting in a nearly 4-fold increase by 3mon
postnatal. In contrast, MHC contents rose gradually, levels doubling during
development. The pattern in bladder smooth muscle was quite different. Actin
contents rose rapidly in the last third of gestation, increasing -4-fold by term, and
remained stable thereafter (Fig 1). The rise in MHC contents paralleled that of
actin, increasing 2-fold by term and 3.3-fold by 30d postnatal.
The most striking differences between tissues were seen for MHC contents. At
<100d gestation aorta MHC contents were similar to bladder. Beyond lOOd
gestation, values in bladder were ~2-fold greater (p<0.004) than those in aorta.
This difference continued throughout the remainder of development. Differences
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Table 1. Analysis of Variance for Age-grouped Data Comparing Total and Soluble Protein Contents in Aorta and
Bladder Smooth Muscle During Ovine Development ^ , .
Fetal Age Postnatal Age A * *
* * '?* ' * <100 101-130 131-145 1-7 8-21 22-30 86-120 >1yr P-value
Aorta (n) (8) (9) (6) (8) (5) (3) (6) (3)
65±4' 75±6" 86±9" 68±9* 78±12" 82±5"° 100±9° 102±6° 0.025
40±3' 40±3* 41±4* 42±6* 47±7" 55±6" 61±7" 51±9" 0.073
Bladder (8) (9) (6) (8) (5) (3) (6) (5)
55±7' 74±5" 81±7» 86±5° 90±7° 89±3° 86±5" 112±7' 0.004
50±7* 56±4" 68±3" 69±6"* 72±5' 0.001
Values shown are means ± SEM with units of ug/mg weight Results of ANOVA comparing groups are shown by letter
superscripts indicating significant differences where no overlap occurs P-values for ANOVA are shown.
between tissues for actin contents were more variable. Nonetheless, between 131 d
gestation and 21d postnatal, bladder actin contents exceeded those in aorta
(p<0.04).
Myos/w /« /so/brws
MHCs separated by electrophoresis in gels containing 4% polyacrylamide
yielded two protein species at relative mobilities 204 and 200 kDa. No species of
lower relative mass (196 kDa) were observed for any tissue studied. The relative
amounts of the 204 and 200 kDa bands were quantified by densitometry and
expressed as percent of total. Changes in species content during development were
determined as the product of the measured total myosin content and the percent
mass of each species. Subsequently, identification of MHC isoforms within the
200 kDa species was performed by Western analysis.
The predominant MHC species in aortas from mid-gestation fetal sheep
(<100d) was the 200 kDa form, which composed 70 ± 3% of total MHC (Fig 2).
The percentage of 200 kDa species declined rapidly thereafter (R=0.61, p<0.001;
second order) to 35 ± 2% at >3mon. The relative amount of the 204 kDa isoform
rose reciprocally (R=0.64, p<0.001; second order) over the period studied from
30 ± 2% to 65 ± 2%, respectively. Significant differences in the amount of each
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Figure 1. Alterations in actin and myosin heavy chain contents (ng/mg of wet weight) in aorta
and bladder during ovine fetal and postnatal development. Actin and MHC contents include
all isoforms. Each time interval represents n values shown in Table 1. Average time of birth
(~145d gestation) is indicated by the arrow. Significant polynomial regression analyses were
obtained for changes in actin and MHC contents, respectively, with aorta (R=0.62 and 0.52,
p<0.001 each; first order) and bladder (R=0.70 and 0.67, p<0.001 each; second order). Groups
not different as determined by ANOVA are indicated by the same letter.
species were detected between fetuses at <100d gestation and animals >lwk
postnatal (p<0.001 ANOVA). In striking contrast to the aorta, the predominant
MHC species in bladder muscle from mid-gestation fetuses was the 204 kDa form,
which composed 74 ±3% of total MHC (Fig 2). This gradually declined (R=0.84,
p<0.001; first order) to 48 ± 2% at 3mon, while the 200 kDa species increased
(R=0.84, p<0.001; first order) from 26 ± 3% to 51 ± 2%. Values at <100d gesta-
tion significantly differed (p=0.003, ANOVA) from those at >21d postnatal.
Calculation of the tissue content of these MHC species (ug/mg wet weight)
resulted in a pattern distinct from that seen for the relative amounts (Fig 2). In
aorta the 204 kDa isoform content increased 4.3-fold by 3mon postnatal (p<0.01
ANOVA). The 200 kDa isoform content, however, was unchanged throughout
development (Fig 2). In contrast, amounts of both 204 and 200 kDa species in
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Figure 2. Relative and absolute changes in 204 kDa and 200 kDa MHC
isoforms in aorta and bladder during ovine development. (Top panels) Values
were derived by calculating the percent of total staining MHC (204 + 200 kDa)
comprised of each form. Polynomial regression curves are shown as solid lines
through the data to distinguish the two groups. (Middle and lower panels)
Absolute changes in contents of the 204 kDa and 200 kDa MHC isoforms
(Hg/mg of wet weight) in aorta and bladder during ovine development. Graph
properties as described in Figure 1. Significant polynomial regression analyses
for 204 kDa protein were obtained for aorta (R=0.68, p<0.001; first order)
and bladder (R=0.58, p<0.001; second order) as well for 200 kDa protein in
bladder 200 kDa protein (R=0.65, p<0.001; first order). The 200 kDa isoform
content of aorta was unchanged, averaging 1.4±0.1 (xg/mg wet weight.
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Aorta
Std Std Std 88 93 110128 140 2d 16d 29d 3m 4m Std Std Std 88 93 110 128 140 2d 16d 29d 3m 4m
Pit BB SM2 Fetal Postnatal Pit BB SM2 Fetal Postnatal
Bladder
Std Std Std 88 93 110 133 140 2d 17d 30d 3m 4m Std Std Std 88 93 110 133 140 2d 17d 30d 3m 4m
Pit BB SM2 Fetal Postnatal Pit BB SM2 Fetal Postnatal
Figure 3. Representative immunoblots illustrating the change in smooth muscle 200 kDa
isoforms SM2 and MHC-B during ovine development in aorta and bladder. Standards (Std)
included sheep platelet lysates (Pit), MHC-B purified from bovine brain (BB), and adult
myometrial homogenate (SM2). Numbers represent days following conception (term ~145d)
and birth. Separating gels were loaded with protein to yield 200 ng total MHC per sample, as
calculated from MHC contents assessed above.
bladder, increased rapidly and in parallel, with increases of 2.7- and 6-fold respec-
tively (p<0.02 and =0.002, ANOVA).
The 200 kDa MHC species may contain SM2 and/or MHC-B. The develop-
mental dependence of expression of each was determined by immunoblotting
with antibodies specific for SM2 and MHC-B (7). This analysis was used to quali-
tatively assess patterns of isoform expression (Fig 3). Each blot was loaded with
three standards: sheep platelets as a marker for MHC-A, purified bovine brain
myosin as a marker for MHC-B, and adult ovine myometrium as a marker for
SM2. Although we never detected a protein species at 196 kDa, it is possible that
ovine MHC-A may migrate at a different position. We were not able to rule out the
presence of MHC-A in these samples because antibodies against human platelet
MHC-A peptide did not cross-react with sheep platelet protein and polyclonal
antibodies against human platelet MHC-A showed cross-reactivity with MHC-B.
The specificities of anti-MHC-B and anti-SM2 are illustrated on immunoblots in
Fig 3. Although there was no change in aortic total 200 kDa MHC content during
development (Fig 2), the isoform distribution changed dramatically (Fig 3).
MHC-B was abundant prenatally and declined rapidly after birth, while SM2 was
barely detected at early time points prenatally and increased most dramatically
after birth. In striking contrast to the aorta, bladder muscle showed no detectable
expression of MHC-B, even at mid-gestation, whereas SM2 was abundant
throughout development and increased prior to and after birth (Fig 3).
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Figure 4. Isometric force tracings from maternal and fetal smooth muscle
tissues collected near term (130-145d gestation). Indicated tissues were
mounted for force measurements as described. Strips were stretched (A), then
stimulated (T) with 10* M phenylephrine (aorta) or 65 mM KC1-PSS (bladder),
followed by relaxation (1) in Ca^*-free PSS containing 2 mM EGTA.
Jsowerr/'c Force
We compared contractile responses of aorta and bladder smooth muscle strips
from lOOd gestation and near-term fetal sheep with 2-4wk neonates and adults.
Strips of fetal aorta showed no contractile response (Fig 4) to any agent tested
(KC1, phenylephrine, histamine, serotonin, PGF2a, ATP, carbachol, angiotensin
II, or endothelin), whereas strips of bladder muscle gave robust contractions with
KC1 depolarization and carbachol. All strips of adult aorta and bladder
contracted in response to KC1 and other agents. Maximal active stress was deter-
mined from the results of the length-force relations. Strips were stretched in
calcium-containing PSS, stimulated with 65 mM KC1 PSS, then relaxed in
calcium-free PSS containing 2 mM EGTA. Active force was calculated as the
difference between peak force and the resting (passive) force following relaxation
in calcium-free PSS. Bladder muscle exhibited significant tone following stretch,
which was removed after incubation in calcium-free PSS (Fig 4). Values of
maximal active stress are shown in Fig 5. Contraction responses in 1 OOd and term
fetal aortic strips were markedly attenuated compared to vessels from neonates
and adults. Although responses of aortas from fetal animals were unmeasurable,
aortic stress increased to near-adult values soon after birth. In contrast, bladder
muscle generated significant stress at lOOd gestation and values increased 7-fold
during the late fetal period (Fig 5). This was followed by a progressive decline
postnatally.
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Figure 5. Maximal stress generation by
aorta and bladder strips in response to KG
depolarization. Isometric forces were
measured at L<, and normalized to cross-
sectional area as described. Animals were
grouped into early fetal (<100d gestation);
late fetal (130-140d gestation); postnatal
(2-4wk after birth) and adult. Groups not
different as determined by ANOVA are
indicated by the same letter.
100d 130-140d 2-4wk Adult
a
n
b
Bladder
c
T
c
T
100d 130-140d 2-4wk Adult
Myosm LigAtf
In order to determine whether failure of aortic smooth muscle to contract in the
prenatal period arises from a deficit in the excitation process, we measured regula-
tory light chain (RLC) phosphorylation in response to high concentration of
agonist as an index of activation. In the passive state achieved with calcium-free
conditions no phosphorylation was observed in aorta or bladder strips collected
at any age. Consistent with the results of contraction experiments, all muscles that
contracted exhibited about 0.5 mol phosphate/mol RLC at the time of maximal
stress development in response to high concentrations of agonist (Fig 6). These
included neonatal and adult aorta stimulated with lO"-* M phenylephrine as well
as bladder from any developmental stage stimulated with 10"^  M carbachol. In
fetal aortic smooth muscle strips, however, no RLC phosphorylation was
observed in response to 10"^  M phenylephrine consistent with a failure to
contract.
To test the possibility that a deficiency in myosin light chain kinase may
account for a lack of phosphorylation, we performed immunoblotting analysis on
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Aorta Figure 6. Values of myosin regulatory light
chain (RLC) phosphorylation in response
to agonist Muscles treated with calcium-free
PSS showed no measurable RLC
phosphorylation (data not shown). Aortic
strips were treated with 10"^  M
phenylephrine and bladder strips with 10'^
M carbachol. Values for both early fetal and
term fetal aortic strips were 0.0 mol phos-
phate/mol RLC with n=8 for each. N values
for other conditions range from 4 to 8.
100d 130-140d 2-4wk Adult
tissues. Aortic and bladder smooth muscles expressed MLCK throughout devel-
opment. Relative amounts of MLCK were determined by densitometry and
followed by normalization to adult values as 100%. MLCK increased in the aorta
from 79 ± 10% at 1 OOd gestation, peaked at two weeks postnatal (136 ± 13%) and
then declined to 100% in adult (p=0.04, ANOVA). In contrast, no significant
differences in MLCK amount were found with ANOVA among bladder tissues
from the different developmental stages.
DISCUSSION ; =
Fetal and postnatal development are marked by rapid growth accompanied by an
orderly sequence of maturational changes. The maturation of smooth muscle cells
in the walls of hollow organs would be expected to parallel growth and require-
ments for organ function. Results of the present study reveal that in a large
mammal maturation of vascular and visceral smooth muscle tissues, as assessed
by increases in contractile protein content, occurs continuously from early
mid-gestation through the first month of life. Nevertheless, distinct differences are
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seen between the tissues with regard to absolute contents of contractile proteins,
the interconversion of MHC isoforms, and the early onset of contractile function,
leading to the conclusion that bladder smooth muscle matures far in advance of
the vascular smooth muscle of the aorta.
Increases in MHC and particularly actin contents exceed those of total or
soluble protein for both tissues, demonstrating specific up-regulation of the
contractile component of smooth muscle after mid-gestation and providing
evidence of cellular maturation. Comparison between tissues reveals that bladder
contents of soluble protein, actin and MHC exceed those in aorta after lOOd
gestation, leading to the conclusion that bladder muscle growth and maturation is
initiated early in development and proceeds rapidly thereafter. We previously
measured actin and MHC contents in aorta and bladder from male animals over a
more limited developmental period (119d gestation to 33d postnatal) (5). Values
for actin, MHC and soluble protein are similar in respective tissues from female
and male animals during this period; thus, sex per se does not appear to exert
significant effects on processes regulating normal maturation of aorta or bladder
muscle. Previous studies of quantitative increases in contractile protein content
during smooth muscle maturation have focused on late fetal or postnatal periods
(5,10,28,29). By extending our observations to much earlier times in gestation
(72d), we have identified the time around lOOd as an important transition point
for smooth muscle growth, and particularly for increases in contractile protein
content.
MHC isoform expression clearly illustrates the differences in maturational
patterns between the bladder and the smooth muscle of aorta. For example, the
ratio of 204/200 kDa MHC species increases between <100d gestation and 3mon
after birth in aorta, but decreases in bladder over the same period. While plots of
percent MHC species show dramatic relative changes, they provide a limited
picture of alterations occurring during development because the total amount of
MHC varies and because the composition of isoforms within a band of given
molecular mass may be heterogeneous. We therefore analyzed the total contents
of each MHC species and the changes in isoform expression within the 200 kDa
species. Amounts of SMI (204 kDa MHC) increase throughout development in
both tissues, and in bladder values exceed those of aorta by 3- to 5-fold at all times.
SM1 is an exclusive marker of smooth muscle differentiation (1), and its presence
in both tissues confirms that each contains differentiated smooth muscle cells at
mid-gestation. The succeeding increases in SMI content illustrate an important
quantitative attribute of smooth muscle maturation not previously described.
Immunohistochemical studies will be required to determine whether maturation
of all cells within a tissue occurs gradually and in parallel, or whether individual
cells mature more rapidly but in gradual succession. Distinct populations of cells
have been shown to exist within different tissues (17,30,31), thus the latter cannot
be ruled out. Abundant SM-MHC, as well as actin and other contractile proteins,
may arise from transcriptional, translational or post-translational regulatory
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processes that constitute a significant facet of the mature smooth muscle pheno-
type. Mechanisms regulating contractile protein quantities require future investi-
gation.
Qualitative analysis of isoforms within the 200 kDa MHC species demon-
strates further dramatic differences between aorta and bladder. Where MHC-B
predominates before birth in aorta, no MHC-B was detected in bladder at any
stage. In ovine aorta MHC-B was gradually replaced by SM2 after birth. These
results are consistent with those of others in which postnatal increases in SM2
fraction lead to adult values in human (13,16), rabbit (14,18), and mouse (15)
aorta, as well as swine carotid artery (32), accompanied by reciprocal declines in
MHC-B (13,18). The replacement of non-muscle isoforms of cytoskeletal
proteins, such as /-caldesmon, a-tropomyosin-2b and MHC-B, with smooth
muscle isoforms constitutes a maturational transition in smooth muscle (33,34).
Striking in the present study was the observation that no MHC-B was expressed in
bladder after 90d gestation, supporting the conclusion that maturational transi-
tions are accelerated in bladder smooth muscle. Postnatal alterations in rat and
mouse bladder 204 and 200 kDa proteins are modest and resemble those seen in
postnatal sheep (15,32). While the specific contributions of MHC isoforms to
muscle function are not fully defined, SM1 and SM2 are associated with a contrac-
tile phenotype, whereas MHC-B is associated with growth conditions either
during development, disease or cell culture (9,34,35,36). The present finding that
little or no MHC-B is expressed in bladder muscle during fetal maturation
suggests that this muscle has a fully expanded population of mature smooth
muscle cells at an early stage as compared to aorta.
Maturation of contractile protein content and phenotype should be reflected
in an increased contractile capacity during development. This tenet is
well-illustrated in the bladder muscle, where active stress increases some
seven-fold between 100 and 140 days gestation reflecting significant increases in
actomyosin content over the same period. Moreover, the increase in stress genera-
tion does not appear to result from changing responsiveness to stimulation during
fetal growth because both MLCK content and the fraction of myosin
phosphorylated in response to maximal agonist were similar at 100 and 140 days
gestation. Stress generation has also been reported to increase with fetal develop-
ment in pig tracheal smooth muscle (37). In contrast, aortic muscle from fetal
sheep was unresponsive to a host of agonists and failure to contract was associated
with a lack of myosin phosphorylation, in spite of significant expression of
MLCK. We previously found contraction and myosin phosphorylation to be
inhibited in near-term femoral arteries (2). These results, in combination with
generally lesser sensitivity of the fetal ovine systemic vasculature to vasoconstric-
tors as compared to the placental circulation (4,10), support the notion that some
components of systemic vascular smooth muscle are functionally immature up to
the time of birth. This immaturity is reflected in the expression of the nonmuscle
MHC-B in these vessels, which decreases following birth. However, the lack of
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contractile responsiveness in these vascular muscles appears less likely to result
from immaturity of the contractile apparatus than from deficits in the excitation
pathway. This tentative conclusion is based on following: 1) agonists do not elicit
myosin phosphorylation indicating failure to elevate intracellular calcium
required to activate MLCK; 2) vascular muscle contains amounts of smooth
muscle MHC and actin prior to birth that are comparable to amounts found in the
contractile bladder muscle at lOOd gestation; and 3) contractile responsiveness is
observed within a week after birth at which time changes in the contractile protein
profile are minimal. Further investigations will be required to determine whether
maturation associated with the onset of contractility involves the induction of
receptor expression, coupling pathways, ion channels or other regulatory
proteins. **>P?*{?i
Fol lowing bir th, aort ic stress increased to near-adul t values. A similar pa t te rn
was seen in second generat ion pu lmona ry arteries from sheep (28); however
others have noted increases in m a x i m u m contract i le response between neonata l
and adul t aor tas from rat (29), gastric myocytes from rabbi t (38), and carot id
artery from sheep (39). M o r e surprising in the present study was the decline in
stress generat ion observed in bladder muscle with pos tnata l ma tu ra t ion . This
could not be a t t r ibuted to differences in ac tomyosin contents , nor levels of activa-
tion as assessed by myosin phosphory la t ion . N o references to postnata l changes in
bladder stress were found in the l i terature. Declines in stress generat ion might be
accounted for by age-dependent changes in cellular density or or ienta t ion in the
bladder wall .
The advanced maturation and growth of bladder smooth muscle as compared
to that from aorta supports the notion that demands for organ function may influ-
ence the developmental course. The aorta is a conduit vessel, thus the need for
rapid maturational changes before birth may be minimal. In contrast, the bladder
is functional early in the midtrimester, excreting urine at a rate of 7-10 ml/kg-h,
which increases to 30-40 ml/kg-h at term (11,12). It has been established that the
differentiation of smooth muscle in the bladder is dependent upon interactions
with the epithelium (40). It remains to be determined whether the accelerated
maturation of the bladder is also dependent upon epithelial signals that may be
influenced by bladder filling and/or distension. In addition, bladder smooth
muscle cells may be independently influenced by these mechanical forces.
Contractile responses of the fetal aortic and bladder smooth muscle tissues were
consistent with the above notion in that only the bladder muscle exhibits robust
force generation in response to stimulation.
The period of fetal development supports growth and maturation of organ
systems essential for survival to birth and independent life thereafter. Owing to
the relatively large size of the fetus, the ovine model allows analysis of functional
56 CHAPTER 4 AT8OA * 3 i S 13S •
properties of smooth muscle tissues during development. These and our previous
results demonstrate a relation between early onset of organ function and acceler-
ated maturation of its smooth muscle component during ovine fetal development
(2,5). Whether maturation is brought about by neuronal, hormonal, paracrine
and/or mechanical factors remains to be investigated. Smooth muscle differentia-
tion is a complex process that involves the orderly activation of genes encoding
smooth muscle-specific proteins such as SMI. In quantifying SMI protein
contents (as well as those of total MHC and actin) at multiple points through
development, this study distinctively illustrates that maturation following differ-
entiation includes increases in contractile protein content over the last third of
ovine gestation and through the first month postnatally, laying the foundation for
increasing contractile capacity (29,38,41). Further studies will be required to
determine threshold conditions leading to contractile function, as well as specific
queues promoting maturation during development.
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In fetal sheep, umbilical responsiveness to angiotensin II exceeds systemic
vascular responsiveness. Fetal systemic vascular smooth muscle (VSM) exhibits
an immature phenotype with decreased contractile protein contents, low 200
kDa myosin heavy chain (MHC) SM2, and significant nonmuscle MHC-B
expression, whereas umbilical VSM phenotype is incompletely described. We
tested the hypothesis that differences in vascular responsiveness could reflect
dissimilarities in VSM phenotype. Actin, MHC, MHC-isoforms and active
stresses were compared in strips of femoral arteries and aorta from near-term
fetal (n=12) and adult (n=12) sheep to those in external and intra-abdominal
umbilical arteries. Actin contents in fetal femoral artery and aorta were less
(p>0.006) than in external umbilical artery (7.37±1.4 and 7.53±0.7 vs 21.6±2.2
|Xg/mg wet weight, respectively) as were MHC contents (3.17+0.4 and 2.84±0.3
vs 7.16±0.7, respectively). Whereas 204 and 200 kDa MHC were expressed
equally in fetal systemic arteries, umbilical and adult arteries predominantly
expressed the 204 kDa isoform (SMI); only fetal systemic VSM expressed
MHC-B. Fetal systemic artery stresses and myosin light chain phosphorylation
were less those that in umbilical and adult arteries (p<0.001). Compared to
umbilical and adult arteries, fetal systemic VSM is biochemically and function-
ally immature; thus umbilical VSM demonstrates precocious maturation resem-
bling adult VSM in protein expression and function.
Key words: Fetal sheep, myosin heavy chain isoforms, smooth muscle
phenotype, active stresses, myosin light chain phosphorylation.
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The maintenance and regulation of the umbilical-placental circulation is crucial
for fetal growth and well-being. In fetal sheep this vascular bed is sensitive to
several vasoconstrictors, especially angiotensin II (1,2,3,4). This responsiveness
has also been observed in human umbilical arteries studied m f/fro (5,6,7). In
intact fetal sheep the umbilical circulation is more sensitive to angiotensin II than
the systemic vasculature (1,2,3,4). However, the mechanisms responsible for
these differences in vascular reactivity are unclear. One explanation is that the
contractile protein composition and therefore the contractile capacity of vascular
smooth muscle (VSM) in umbilical and systemic arteries differ.
In the adult, systemic VSM modulates arterial pressure and mediates
responses to numerous stimuli. These differentiated VSM cells express a unique
assortment of contractile and structural proteins, reflecting a mature "contrac-
tile" phenotype (8,9). In these cells contraction results from the interaction of
actin in the thin filaments and myosin in the thick filaments. Myosin molecules are
composed of six subunits: two heavy chains, two regulatory and two essential
light chains. The carboxyl-terminal ends of the myosin heavy chains (MHC) form
a coiled-coil tail that polymerizes to form thick filaments. The amino-terminal end
is folded in a globular head containing binding sites for actin and Mg^-ATP as
well as for each of the light chains and is the site of chemo-mechanical
transduction associated with Mg^*-ATPase activity. Smooth muscle contraction
is triggered by a rise in cytosolic calcium leading to phosphorylation of the myosin
regulatory light chains, which permits actin to activate myosin Mg^+-ATPase
(10,11). In mature VSM these components of the contractile mechanism are
present and functional.
In several species, including fetal sheep, a model widely used to study cardio-
vascular development, the expression of contractile proteins in VSM is develop-
mentally regulated in a tissue specific manner (12,13,14,15,16). In fetal sheep
actin and MHC contents in systemic arteries are quite low throughout the
majority of gestation, increasing just prior to term and during the immediate
postnatal period (12,13). There also are changes in expression of the MHC
isoforms, at least 4 of which are expressed in vertebrate smooth muscle
(17,18,19,20). The smooth muscle MHC isoforms, SMI (204 kDa) and SM2
(200 kDa), are alternatively spliced products of a single gene and are exclusively
expressed in cells of smooth muscle lineage (21). They differ in their
carboxyl-terminal tail sequence and exhibit different patterns of expression
during VSM development, with SM2 expression increasing in mature or
"contractile" tissues (22,12,13,14,18,23,9). MHC-B, also 200 kDa, is derived
from a separate gene, and its expression is associated with the "synthetic" pheno-
type of smooth muscle cells (18). It is found in nonmuscle cells (24), smooth
muscle cells in culture (24,25), and developing fetal VSM (12,13,17,18,26). Its
expression declines during development (12,13,18). MHC-A, also a nonmuscle
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isoform, is 196 kDa and is derived from a third gene (17,27). It is primarily
expressed in platelets (26), but also in some fetal tissues, where it is developmen-
tally regulated (14,28), and in cultured smooth muscle cells (17,25). The relation-
ship between the patterns of VSM protein expression and function during
development are unclear; however, we (12) have recently observed that stress
generation may be attenuated when MHC-B is present and SM2 content is low.
This pattern of protein expression may also differ amongst arteries in the devel-
oping fetus, but this has not been fully explored.
To the best of our knowledge, contractile phenotype and VSM contractile
function in umbilical and systemic arteries have not been compared. Therefore,
the purpose of the present study was to determine: 1) if differences in VSM protein
expression exist in umbilical and systemic arteries from near-term fetal sheep, 2) if
differences in protein expression are associated with different capacities to
generate stress, and 3) whether umbilical artery VSM resembles adult VSM and
thus is highly specialized in the fetal vasculature.
METHODS
Tj'sswe
Near-term fetal (n=12; 130-145d of gestation, term ~145d) and maternal (n=12)
sheep were killed by rapid intravenous injection of pentobarbital sodium (50
mg/kg) to the mother via the external jugular vein. Segments of abdominal aorta
and femoral artery were quickly obtained from fetal and adult animals as well as
segments of external and intra-abdominal umbilical arteries from fetuses and
placed into iced physiologic buffered solution containing (in mM): 137.0 NaCl,
2.7 KC1, 10 Na2HPC>4,1.76 KH2PO4,0.1% diethyl pyrocarbonate, pH 7.4. We
obtained segments of both external (from the mid-third of the umbilical cord) and
intra-abdominal umbilical artery since they represent a continuum of this vessel
and we (29) recently observed differences in angiotensin II receptor expression in
these two portions of the umbilical circulation. Arteries from pregnant ewes were
used since we (30,31) previously reported that neither the protein contents in nor
the stresses generated by systemic blood vessels are altered during ovine preg-
nancy. Endothelium and adventitia were removed from the arteries with a soft
cotton swab and sharp dissection, respectively. Strips of tissue were cut, blotted
dry to remove excess water and capillary blood, frozen in liquid nitrogen, and
stored at -80"C until studied. Additional segments were obtained in order to
measure stresses (see below). These studies were approved by the Institutional
Review Board for Animal Research.
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Prote/w
Sodium dodecyl sulfate (SDS) homogenates were prepared from 10-20 mg
samples of frozen tissue as previously reported (13,31). Briefly, homogenates
were divided into two aliquots. One was subjected to centrifugation at 10,000 x g
for 2min and the supernatant removed to determine the soluble or cellular protein
in each sample. The other sample was not centrifuged and was used to determine
the total homogenate protein. Aliquots of both samples were analyzed for protein
content by BCA reagent (Pierce, Rockford, 111.). Aliquots of the supernatant
containing bromphenol blue and 2-mercaptoethanol were subjected to SDS-
PAGE, using 3-20% and 4% polyacrylamide gels to determine the contents of
total actin and MHC and the relative amounts of MHC isoforms, respectively. For
each tissue mini-gels were loaded with 20-40 ug of soluble protein and subjected
to electrophoresis at 200 V until the dye front reached the bottom of the gel. Gels
were stained with coomassie Brilliant Blue overnight and appropriately destained
to remove background staining. Stained gels were scanned, each lane in duplicate,
with a laser densitometer (LKB Instruments, Inc., Stockholm, Sweden) to estimate
the relative amounts of actin, MHC and MHC isoforms. Differences between
measurements were <5%, and values for each band were averaged. The fraction of
stained protein accounted for by actin and MHC was converted to micrograms
using the total protein quantified by BCA reagent in each sample. Values are
expressed as |ig/mg of wet weight.
SDS-P.AGE
Using the supernatant extracts of fetal and maternal aorta and femoral artery as
well as external and internal umbilical artery, ~200ng of total MHC were loaded
and separated on 4% polyacrylamide gels. Proteins were electrophoretically
transferred to nitrocellulose paper at 80 m A overnight in the presence of methanol
(20%) and SDS (0.1%). Blots were then blocked for lh in a buffer that contained
powdered milk (0.3% wt/vol), incubated for 4h with blocking buffer containing
specific antiserum against either SM2 or MHC-B, (1:4000 and 1:20,000 respec-
tively), and then incubated with goat anti-rabbit IgG conjugated with horseradish
peroxidase (1:15,000). Antibodies to MHC isoforms were generated against
short peptides derived from sequences unique to the carboxyl-terminal tail of each
isoform as described by Chern et al (13). Regions containing MHC isoforms were
visualized by enhanced chemiluminescence (ECL, Amersham International PLC,
England). The blots were kept in the ECL-developing solution for lmin, exposed
on film for 5sec and then developed.
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Immediately following dissection, segments of external umbilical artery and fetal
and adult femoral artery were fixed in 10% neutralized formalin, paraffin-
embedded, and stained with hematoxylin-eosin or elastin van Gieson for imaging
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Segments of arteries were placed in chilled physiologic saline solution (PSS)
containing (in mM): 120.5 NaCl, 4.8 KCl, 1.2 MgSC>4, 1.2 NaH2PC>4, 20.4
NaHCO3, 1.6 CaCl2,10 dextrose and 1 pyruvate. The adventitia was removed,
and the arteries were opened along the long axis of the vessel. The endothelium
was removed by gently swabbing with a cotton swab; the efficiency of this method
has been confirmed using histochemistry. Strips of equal width were cut parallel to
the cellular long axis (i.e., parallel to the vessel circumference) with a double
bladed cutting tool as previously described (30). Strip widths were fixed at 1.3
mm.
The strips were tied at one end with 6-0 silk that was attached to a Grass
FT.03C force transducer; the bottom of the strip was clamped in a plexiglass
holder attached via a stainless steel rod to a calibrated mechanical drive to adjust
muscle length. Isometric force was recorded on a Grass model 7D polygraph. The
strips were suspended in 25 ml jacketed muscle baths containing PSS bubbled with
a 95% C>2-5% CO2 gas mixture to maintain a pH of 7.4 at 37°C. Length-force
relationships were determined using methods previously reported in order to
compare maximal active force (Fo) at comparable muscle lengths (LQ) (30,32).
Strips were stretched 0.5 g initially and length was measured; this was followed by
equilibration for lh. The PSS was then removed from each bath and replaced with
65 mM KCl (KCl isotonically replaced NaCl in PSS). Maximal force obtained in
response to KCl depolarization at a given length was taken as the total force.
Passive force contributed by connective tissue in the strip was obtained after the
tissue was placed in Ca^-free PSS containing 2 mM ethylene glycolbis (p*-
aminoethyl ether)-N,N,N',N'-tetra-acetic acid, eliminating force contributed by
contraction of smooth muscle cells. After obtaining a value for passive force,
Ca-^-free PSS was removed and replaced with Ca^-containing PSS. After
re-equilibration, the tissue was stretched to a new length, and the stimula-
tion-relaxation protocol was repeated. There were no observable effects of EGTA
on responses to repeated contractions. Active force generated by the arteries was
obtained by subtracting the passive from total force at the respective length. The
length at which FQ occurred was defined as the optimal length (LQ) for each muscle
strip. After this procedure, tissues were blotted and weighed. Tissue cross-
sectional area was calculated based on the weight, density, and length of the tissue
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at LQ. Stress (N/m^) was calculated by dividing the active force at optimal length
by the cross-sectional area (30,32).
A
Strips of umbilical artery and fetal and adult femoral artery were mounted for
measurement of isometric force and quick-frozen with tongs precooled in liquid
nitrogen either at rest or at the time of maximum contraction, using 10"^  M
phenylephrine for femoral arteries and 10"^  M 5-hydroxytryptamine, respec-
tively. The frozen muscle was weighed, placed in frozen slurry of trichloroacetic
acid (10%, wt/vol) in acetone that contained DTT (lOmM), and allowed to thaw
in order to denature cellular proteins. Thereafter the muscle was placed in 60 vol
of trichloroacetic acid (10%, wt/vol) and DTT (lOmM) and homogenized. The
precipitated protein was washed with diethyl ether and then suspended in
urea-glycerol buffer for electrophoretic analysis of light chain phosphorylation by
immunoblotting (31,32). Samples were subjected to electrophoresis for lh at 400
V in a gel containing 10% polyacrylamide and 40% (vol/vol) glycerol. Protein was
transferred to nitrocellulose paper and nonphosphorylated and phosphorylated
forms of the light chain were localized by western blotting with antibodies against
bovine tracheal myosin light chain (1:10,000) and peroxidase-conjugated goat
anti-rabbit IgG (1:15,000) with ECL. Relative amounts of nonphosphorylated
and phosphorylated light chain were quantified by laser densitometry.
I7»jfe/7icfl/ arrery respo«ses
Human umbilical arteries have been extensively studied /'« wfro and shown to
respond differently to several constrictors (5,6,7). Similar studies of ovine umbil-
ical arteries, however, are rare (33). We, therefore, characterized ovine umbilical
artery responses to several agonists. Strips of external and internal umbilical
artery were cut and hung in muscle baths as earlier described. The strips were
stretched to their optimal length as determined by length-force calculations, using
three stretches of 1.5 mg for 20min each. The strips were then stimulated twice
with 65 mM KC1. All strips were relaxed with Ca^-free PSS after each contrac-
tion. The strips of external and internal umbilical artery were subsequently stimu-
lated with 10"* M phenylephrine (PE), 1(H M histamine (Hist), 10^ M
5-hydroxytryptamine (5-HT; serotonin), 10-* M carbachol (Cch), 10'-* M
bradykinin (BK), 1(H M PGF2« (PGF), 10^ M PGE2 (PGE), lO'* M angiotensin II
(ANG), and 10"^  M endothelin (ET). These concentrations have been shown to
cause maximal contraction in human umbilical arteries (7).
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All data are reported as means ± SEM. Data were analyzed using Student's t-test
and one-way analysis of variance (ANOVA) with Newman-Keuls correction for
multiple comparisons. Significance was taken as p=0.05.
RESULTS
Tbta/<3«dso/wfo/e
Total protein contents did not differ significantly amongst the fetal and adult
arteries studied (Table 1). Although soluble protein contents in fetal femoral
artery and aorta were similar, values were -40% less than that measured in either
the external or internal umbilical artery (p<0.0001, ANOVA), but did not differ
from that seen in adult femoral artery (Table 1). Furthermore, the soluble/total
protein ratio was greatest in the external umbilical artery when compared to all
other vessels, averaging 0.92, while the internal umbilical artery was similar to the
adult and fetal aorta, demonstrating an intermediate position between fetal
systemic vessels and the external umbilical artery.
To further assess the differences in cellular and noncellular protein contents,
samples of each vessel were prepared for histologic evaluation using hemato-
xylin-eosin to examine smooth muscle contents and van Gieson stain for elastin
contents. As seen in Figures 1A, C and E, the smooth muscle content of the
external umbilical artery is substantially greater than that in either the fetal or
adult femoral arteries. In contrast, the femoral vessels contain relatively greater
contents of elastin, a nonsoluble noncellular protein, than the umbilical artery
(Fig 1B, D and F). It also is notable that the structural pattern of the fetal femoral
artery differs from that of the adult, with more orderly layering of smooth muscle
cells and elastin fibers, and an apparent greater nuclear density. Thus, differences
in vessel architecture are evident.
Acft"« and MHC contends
Actin contents in the fetal femoral artery and aorta did not differ, averaging 7.5
ug/mg wet weight, but were -65% less (p=0.006) than those measured in either
umbilical artery (Fig 2A), which averaged 20 (ig/mg wet weight. Actin contents in
the fetal systemic arteries were also significantly less than those measured in the
respective adult vessels, which more closely resembled that seen in umbilical
arteries (Fig 2A).
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Table 1. Total and soluble protein contents (ug/mg wet weight) in fetal and adult arteries.
Fetal aorta (n=6)
Fetal femoral (n=7)
Internal umbilical (n=5)
External umbilical (n=5)
Adult aorta (n=5)
Adul femoral (n=7)
Total
85.8
85.0
98.1
73.8
104
92.2
protein
± 9.0"
± 5.4"
± 11.0"
± 14.3"
± 3.8"
± 7.5"
Soluble
40.9 ±
37.1 ±
63.6 ±
63.2 ±
57.3 ±
35.0 ±
protein
4.2"
3.6"
5.2*
5.8^
5 >
3.1"
Soluble/Total ratio
0.49 ± 0.05"^
0.43 ± 0.02"
0.68 ± 0.09''
0.92 ± 0.11'
0.55 ± 0.04^
0.38 ± 0.03"
Values are means ± SEM. Different letters within columns denote significant differences between
tissues with p<0.0001 by ANOVA, while the same letter denotes values that are not significantly
different.
Although MHC contents did not differ between fetal and adult systemic arteries
(Fig 2B), the MHC contents in the external and internal umbilical arteries were
>2-fold higher than those measured in all other vessels studied (p<0.0001,
ANOVA).
The relative and absolute contents of the 204 and 200 kDa MHC-isoforms
present in samples of fetal and adult VSM were determined from densitometric
scans of the proteins separated on 4% polyacrylamide gels. Only 2 MHC bands
were observed for each artery studied, confirming our prior observations for
ovine fetal aorta that the 196 kDa protein could not be identified (13). The 204
kDa protein accounted for -50% of the total MHC in the fetal femoral artery and
aorta. In contrast, it accounted for >62% (p=0.0001, ANOVA) of MHC in the
external umbilical artery and both adult arteries; the internal umbilical artery was
intermediate at 57%. Therefore, the relative amount of the 200 kDa protein in
fetal systemic VSM (45-50%) exceeded that in the external umbilical artery and
adult VSM, (27-36%; p<0.0001, ANOVA); again the internal umbilical artery
was intermediate with ~45% of MHC protein the 200 kDa isoform. When we
determined the absolute contents of the 204 and 200 kDa proteins, which take
into account differences in total MHC content, the values were similar in the fetal
systemic arteries, averaging -1.5 Hg/mg wet weight (Fig 3). In contrast, the
content of the 204 kDa MHC-isoform exceeded that of the 200 kDa protein in
both umbilical and adult arteries, a value that was >2-fold higher than the 200
kDa protein in both external umbilical artery (p=0.001) and adult femoral artery
(p=0.0009; Fig 3). Compared to all systemic arteries, the contents of both the 204
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Figure 1. Representative examples of fetal femoral artery (A and B), adult femoral artery (C
and D) and external umbilical artery (E and F) stained with hematoxylin-eosin (A, C and E) to
assess smooth muscle content and van Gieson stain to assess elastin content (B, D and F).
Femoral artery photomicrographs are at 20x in order to permit a comparison of size, cell distri-
bution and architecture, whereas umbilical histology is shown at lOx because of vessel size.
Arrow heads denote vascular endothelium, arrows eiastin fibers, m the media, and a the
vascular adventitia. •»» >^ ' •' ' -
and 200 kDa proteins were greater in umbilical arteries, reflecting the greater total
MHC content (Fig 2B).
Since the 200 kDa protein could consist of either the smooth muscle isoform
SM2, the fetal nonmuscle isoform MHC-B, or both, we performed western
immunoblot analyses to determine the expression of these two isoforms in each
artery studied using specific antisera (13). All of the arteries expressed SM2 (Fig 4);
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heavy chain (B) contents in arteries
obtained from near-term fetal and adult
sheep. Different letters denote significant
differences between tissues (p=0.006 by
ANOVA), while groups not significantly
different from each other are noted by the
same letters. See the Table for the number
of animals within each tissue group.
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204 kD Figure 3. Contents of 204 and 200 kDa
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myosin heavy chain species in arteries
obtained from near-term fetal and adult
sheep. Values are means ± SEM. Numbers
of animals studied is noted in Table 1.
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Figure 4. Representative immunoblots of 200 kDa myosin heavy chain-isoforms in fetal and
adult arteries. The standards (Std) for the SM2 and MHC-B were adult ovine myometrium and
purified bovine brain myosin (8), respectively. Approximately 200 ng of total myosin heavy
chain were loaded in each lane.
however, SM2 expression was substantially less in fetal systemic arteries
compared to either umbilical artery or the adult arteries. In contrast, only the fetal
femoral artery and aorta expressed MHC-B; there was no evidence of this isoform
in any of the umbilical or adult arteries examined (Fig 4).
Cowfnarcf/ow responses
Active stresses were determined for each artery with vascular strips obtained from
four additional near-term animals and performed in duplicate. Although contrac-
tion responses could be elicited by vascular strips obtained from both umbilical
arteries and either adult vessel with 65 raM KC1 or 10"^  M phenylephrine,
responses by strips of fetal aorta and femoral artery were greatly attenuated to
both KCI and a-stimulation as well as several other agonists, including histamine,
serotonin, PGF2a, ATP, angiotensin II, and endothelin (data not shown). As
summarized in Figure 5, stress generated by fetal systemic arteries in response to
KCI, which by-passes potential maturational differences in receptor densities or
coupling, were significantly less than those observed with the external umbilical
artery (p<0.0001, ANOVA), which, in contrast, generated active stresses similar
to those measured for both adult arteries. It is notable that responses by the
internal umbilical artery were again intermediate between the external umbilical
artery and fetal systemic vessels.
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Figure S. Summary of active stresses
obtained with strips of fetal and adult arte-
ries using 65 mM KG at optimal length.
Tissues were obtained from 4 animals, each
studied in duplicate. Different letters denote
significant differences between groups
(p<0.0001, ANOVA), while the same letter
signifies that groups are not significantly
different. Values are means ± SEM.
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Myos/w //g/jr
The primary regulation of force in smooth muscle occurs via Ca^+-dependent
phosphorylation of the myosin regulatory light chain (10,11). We, therefore,
determined in studies of tissues from two additional animals whether the
decreased stress generation in fetal systemic arteries was associated with attenu-
ated levels of myosin light chain phosphorylation. At the time of maximum
stresses (~lmin) obtained by external umbilical arteries (10-* M serotonin) or
adult femoral arteries (10~^  M phenylephrine), there was evidence of 45-57%
phosphorylation of the myosin regulatory light chain (Fig 6A and 6B). In contrast,
following application of 1(H M phenylephrine to fetal femoral arteries, there was
no phosphorylation (Fig 6C) or stress observed. Interestingly, in order to detect
regulatory light chain in homogenates of fetal femoral arteries, 5-times the sample
volume was required to be loaded as compared to maternal femoral arteries.
respowses
To determine the contractile responses by ovine umbilical arteries to several
agonists, studies were performed comparing responses by external and internal
umbilical arteries from near-term fetal sheep using doses reported by White (7).
The data have been normalized as a percent of the response to 65mM KC1, which
represents 100%. The external umbilical artery (Fig 7A) constricted in the pres-
ence of each agonist examined with the exception of bradykinin. However, only
5-hydroxytryptamine elicited a response that significantly exceeded that seen
with KC1, generating 4-fold greater stresses than KC1 (p<0.0001, ANOVA). The
internal umbilical artery demonstrated a similar pattern of responses (Fig 7B); but
unlike the external umbilical artery it was unresponsive to angiotensin II.
7 2 C H A P T E R 5 !7.'..'•••» ; •••••.• '; " ? * 3 T J I . A ' . : M * { 3 T * Y * < I V A J * . ' • ' : :~ "
* « ^ K svo>r ••- ,nx STD PE PE (10"'M)
•••• - A '
5-HT 5-HT (10'M)
PE PE (10'M)
EGTA + +
Ca^ - - + +
Figure 6. Representative immunoblots of regulatory light
chain phosphorylation in adult femoral artery (Row A),
external umbilical artery (Row B) and fetal femoral artery
(Row C). Tissue homogenates (with STD being bovine
tracheal) were subjected to electrophoresis (see Methods)
which separates the non-phosphorylated (upper band)
from the phosphorylated (lower band) light chain. Lanes
2 and 3 show absence of phosphorylation when vascular
strips are at basal tension in the presence of EGTA and the
absence of Ca^* in the baths. Lanes 4 and 5 show 45-57%
phosphorylation at the time of maximum contraction by
adult femoral arteries with 1CH M phenylephrine (PE)
and by external umbilical arteries with 10"' M
5-hydxroxytryptamine (5-HT). Fetal femoral arteries
required 5-fold greater sample volume to detect regula-
tory light chain, and phosphorylation was not observed
with 10 -* M PE.
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Figure 7. Contraction responses to multiple agonists by strips of external (A) and intra-
abdominal (B) umbilical arteries obtained from near-term fetal sheep. Responses are presented
as the percent of the response observed with 65 mM KG. Doses and abbreviations are defined
in Methods. Arteries from 4 fetal sheep were studied, each in duplicate. Values are means ±
SEM.
DISCUSSION ••;-:
In fetal sheep vascular responses to infused vasoconstrictors may be less than
those seen in adult animals (4,34). This could reflect differences in the clearance of
these agents (3), the absence or immaturity of specific receptors necessary for the
transduction of these messages (28,35) or the relative immaturity of fetal VSM as
compared to the adult (12,13,36). In addition, significant differences exist
between umbilical and systemic responses to vasoconstrictors (1,3,4). For
example, in intact fetal sheep with chronically implanted flow probes, the umbil-
ical vascular bed is more sensitive to angiotensin II over a wide range of doses than
either the hindlimb vasculature (2) or the systemic vasculature as a whole (4).
These dissimilarities, however, are not explained entirely by differences in the
receptor subtype expressed in the two vascular beds (2). Thus within the fetal
compartment there is increasing evidence of important differences in vascular
maturation and function (1,2,3,4,37,38). The expression of contractile proteins
in ovine fetal systemic VSM is developmentally regulated and prior to birth a
"synthetic" phenotype of VSM is predominant (12,13). However, it is unclear
which factors account for the differences in umbilical and systemic vascular
responsiveness and what role the expression of VSM contractile proteins might
play. To address these queries we examined the expression and contents of key
contractile proteins in several systemic arteries from fetal and adult sheep as well
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as the umbilical artery and compared this to their capacity to generate stress »«
v/'fro. ,
The contents of actin and myosin in vascular and visceral smooth muscle are
developmentally regulated (13,16,24), and in ovine aorta and bladder values are
extremely low until the end of gestation and during the immediate postnatal
period (12,13). Whereas actin contents in aorta of term fetal sheep increase
~2-fold at term, resulting in values that are half of those seen in the adult, MHC
contents have reached values approaching adult levels. The pattern of change in
total and soluble protein contents resemble that seen with myosin, i.e., at term
gestation values approach that seen in the adult (12). In the present study, contents
of actin, myosin, and protein in near-term fetal and adult systemic arteries were
similar to those previously observed. However, umbilical artery actin and MHC
contents were 2.5- to 3.0-fold greater than those observed in fetal systemic
arteries. Further, total myosin content was 2-fold greater than that measured in
adult vessels. The greater contents of actin and MHC in both umbilical arteries
were associated with a greater soluble protein content, suggesting that there is not
only more contractile protein in umbilical arteries, but also more smooth muscle,
particularly in the external umbilical artery. This conclusion is further supported
by histologic comparison of the vessels. The intra-abdominal portion of the
umbilical artery was intermediate in this regard and in all other aspects, suggesting
it serves as a transitional artery between the fetal systemic and umbilical
vasculature, an observation consistent with recent findings regarding angiotensin
II receptor subtype expression in fetal sheep (28).
In adult mammals, VSM contains predominately the smooth muscle MHC
isoforms, SMI and SM2, and the SMI species is the more abundant isoform
(14,30,39). Furthermore, SM2 accounts for all or nearly all of the 200 kDa species
in adult VSM (14,40). Thus adult VSM consists primarily of the "contractile"
smooth muscle phenotype. In contrast, systemic arteries from the developing
ovine fetus predominantly express the 200 kDa species, and SMI does not achieve
adult levels until 3-4mon postnatal (12,13). Furthermore, the 200 kDa species in
developing systemic VSM consists primarily of the nonmuscle isoform MHC-B
until after birth (12,13). This pattern of protein expression reflects the predomi-
nance of a "synthetic" smooth muscle phenotype, which has been identified in
proliferating smooth muscle cells in culture and within arteriosclerotic
neointimas (24,25,26) and is associated with the potential for VSM replication
(41). These differences in MHC-isoform expression between fetal and adult
systemic VSM were also evident in the present study. In contrast, the umbilical
arteries more closely resembled mature adult arteries, i.e., predominantly
expressing the SMI isoform and having no evidence of MHC-B expression.
Although we have only examined five systemic fetal arteries to date, each has
consistently expressed MHC-B, and its expression has decreased with increasing
age (12,13, unpublished observations). Notably, the bladder is the only other
smooth muscle thus far identified in fetal sheep that does not express MHC-B.
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Like the umbilical artery, it too has a predominance of SMI (12,13). Thus umbil-
ical artery VSM development is precocious within the fetal vascular compartment
and unlike systemic VSM, demonstrates only a "contractile" VSM phenotype at
term. Advanced differentiation of the ductus arteriosus has also been described
recently (37,38); however, MHC-B expression was not examined. Since the
umbilical artery and ductus arteriosus constrict at or soon after birth in order to
redirect cardiac output, their accelerated maturation of VSM may be unique to the
fetal vasculature and related to adaptative alterations necessary following birth.
Responses by vascular strips of fetal femoral artery and aorta were signifi-
cantly attenuated compared to adult arteries for all agonists examined, including
KCI. This is consistent with studies comparing fetal, newborn and adult systemic
arteries from sheep, rabbits and rats (16,42,43,44). Although there were quantita-
tive differences in the measured responses to KCI or other agonists between
studies, reflecting the use of strips versus rings, arteries from immature animals
were consistently less responsive. In contrast, the external umbilical artery gener-
ated stresses comparable to those seen with adult vessels while the internal umbil-
ical artery stresses were intermediate. These results clearly support prior
observations that the "synthetic" phenotype of VSM, for which MHC-B serves as
a marker, is associated with decreased functional capacity (45,46). Failure of fetal
systemic arteries to contract to several agonists may be due to deficits in excita-
tion-contraction coupling. Our finding that supramaximal concentrations of
agonist did not elicit myosin light chain phosphorylation in fetal femoral arteries
suggests these agonists did not elevate intracellular calcium concentrations;
however, a more detailed time course will be required to establish if this is the case.
In preliminary studies, we have found significant expression of calcium-
calmodulin-dependent myosin light chain kinase in fetal arteries at this stage of
development. Thus it remains to be determined if the immature VSM phenotype is
associated with fewer receptors, channels, or other components required for exci-
tation-contraction coupling. Supporting this notion is our recent observation that
only the AT2 subtype of the angiotensin II receptor, which does not couple to
contraction (47), is expressed in ovine fetal systemic arteries (2,29). It remains
unclear, however, whether differences in contractile protein composition between
fetal and adult arteries also contribute to the attenuated stresses. While total
MHC contents were similar in fetal and adult systemic arteries, actin contents
were less and interestingly, immunoreactive regulatory light chain contents also
were substantially lower in fetal VSM. Further, MHC-isoform composition
differed, i.e., nonmuscle MHC-B was expressed only in fetal systemic arteries.
Direct activation of contractile proteins by elevating calcium in permeabilized
muscle fibers will be required to directly assess the contractile capacity of fetal
VSM.
Although fetal sheep are extensively used to study cardiovascular develop-
ment /« f zVo and have provided important insights into developmental changes,
important differences may exist between species. While the human fetus cannot be
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studied in detail, the umbilical artery is readily available after birth, thus its
responsiveness to numerous agents has been thoroughly examined (5,6,7). These
studies, however, have focused on understanding how the umbilical artery closes
at birth. Similar studies of the ovine umbilical arteries are rare (33). We, therefore,
determined if the external and internal umbilical arteries responded differently to
several agonists, and how these responses compared to those observed with
human arteries. Responses by the two segments of ovine umbilical artery were
similar, and 5-hydroxytryptamine elicited the greatest contractile responses by
both arteries, which is consistent with earlier reports for sheep (33) and the human
(5,6,7). Bradykinin, a potent vasoconstrictor in the human umbilical artery (6,7),
however, had no effect on either ovine artery. The reason for this disparity is not
readily apparent. Angiotensin II also contracted the external umbilical artery, but
had no affect on segments of the internal artery. This can be explained by the
expression of ATI receptors in the former and AT2 receptors, which do not
couple to contraction, in the latter (29). Comparing these responses with the
human is difficult since there may be regional differences in angiotensin II receptor
expression (48) and function (6) within the external umbilical artery which will
require further evaluation. Nonetheless, evidence exists in both species that the
umbilical vasculature is quite sensitive to angiotensin II and several other agonists,
further supporting the use of the sheep as a model for studies of cardiovascular
development.
In the present studies we have compared for the first time the differences in
protein expression and function in fetal systemic and umbilical artery VSM in
order to explain previous observations of differences in contractile responses ««
wi>o (1,2,3,4). We have demonstrated that unlike systemic arteries the ovine
umbilical artery predominantly expresses the "contractile" phenotype of VSM
and there are greater contents of actin and total myosin in the umbilical artery.
Moreover, we have shown that the umbilical artery is functionally more like adult
arteries, responding to several agonists. Thus umbilical artery smooth muscle
development precedes that of the fetal systemic vasculature. Additional studies,
however, are needed to determine if the smaller systemic resistance vessels also
demonstrate a slower rate of maturation.
It is now evident that compared to the systemic vasculature as a whole several
arteries within the fetal compartment demonstrate precocious development,
including the ductus arteriosus and umbilical artery (2,37,38). Thus the matura-
tion of fetal VSM cannot be easily characterized by simply studying a single vessel
such as the aorta. It is likely that this differential maturation is associated with
local regulatory mechanisms, which in turn are associated with the specific roles
of these vessels in ensuring fetal adaptation and well-being prior to and after birth.
The present data suggest that the umbilical artery not only actively participates in
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modulating umbilical and placental blood flow, but also may modulate systemic
vascular resistance since this vascular bed accounts for 45-50% of fetal cardiac
output. The slower maturation and development of the systemic VSM, therefore,
may account for the lower arterial pressure seen in fetal and newborn animals, as
well as the prematurely born human neonate. Thus the present observations
provide further evidence to support the suggestion that the umbilical vasculature
plays a more important role than generally considered in regulating fetal systemic
blood pressure and the distribution of cardiac output (2,49).kk-8$oTt«j*iureX- 51
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To characterize changes in myometria! contractile proteins and myosin heavy
chain (MHC) isoforms during ovine fetal and neonatal development and
following pregnancy. We hypothesized that ovine myometrium demonstrates
progressive cellular differentiation and maturation, which begins /'w wtero and
extends into the postnatal period, and that pregnancy causes further cellular
alterations.
Myometrium was obtained from female fetal (72-140d gestation, n=19;
term~145d), postnatal (ld-3mon, n=25) and parous noncycling nonpregnant
(n=9) sheep to measure total and soluble proteins, actin, MHC and MHC
isoforms. Contractile proteins were analyzed by SDS-PAGE and expression of
200 kDa MHC isoforms determined with Western immunoblots.
The contents of total and soluble proteins and actin and total myosin gradually
increase (P=0.003) during ovine development. Although the contribution of
smooth muscle 204 kDa MHC increases (P<0.001) from 23±8% of total MHC
at <100d gestation to 75±2% 3-4mon postnatal, the 200 kDa species falls
proportionately. Before birth MHC-B, a "fetal isoform", is the predominant
200 kDa protein; postnatally, it is replaced by SM2, demonstrating a switch
from a "synthetic" to a mature contractile smooth muscle phenotype. Preg-
nancy is associated with further increases in actin contents and redistribution
of the contents of the 204 kDa and SM2 MHC isoforms.
Although the fetal and postnatal uterus has no known functional demand,
ovine myometrial differentiation and maturation begin in the midtrimester and
continue throughout the postnatal period. Thus changes in smooth muscle
phenotype occur prenatally, as evidenced by a switch from MHC-B to SM2,
which may signal completion of organ development and preparation for adult
function. Pregnancy results in further modifications in myometrial proteins.
Index terms: Myometrium, Development, Myosin, Fetus, Smooth muscle,
Pregnancy.
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INTRODUCTION • !
Normal development of the mammalian uterus is essential for the successful prop-
agation of the species. This dictates not only the number of conceptuses that can be
supported, but also the subsequent growth and postnatal phenotype of the
conceptus (1,2). Uterine development occurs in three stages, organogenesis,
cellular differentiation and maturation, and growth. The first begins with fusion
of the paramesonephric ducts, which determines species specific morphology and
occurs in the ovine fetus between 34 and 55d gestation (3). This is followed by the
development of two distinct layers of mesenchyme and progressive cyto-
differentiation. The inner layer becomes the endometrial epithelium, which has
been carefully studied and described in some detail (1,3,4). The outer layer of
mesoderm is destined to form both the longitudinal and circular layers of the
uterine smooth muscle or myometrium (1,3), and its differentiation, like that of
the bladder (5), appears to be dependent upon the endometrium (6). In most
mammals this occurs postnatally (1,7-9), whereas in the human and ewe this is
observed/« wtero (3,10). Histological evidence suggests that cellular maturation
follows differentiation and proceeds for variable periods of time depending on the
species, but always extends into the postnatal period. Organ growth then occurs
as the female grows and matures. However, the maturational processes of the
developing myometrium are not fully understood, in particular, the characteris-
tics of the smooth muscle phenotype.
Smooth muscle is by far the most abundant tissue in the organs of the urogen-
ital tract, i.e., the uterus and bladder. The phenotypic alterations that occur during
smooth muscle development are derived from the sequential and gradual induc-
tion of differentiation-specific protein markers (11). Smooth muscle myosin
heavy chain (MHC) is exclusively expressed in smooth muscle cells during devel-
opment and is an indicator of the smooth muscle phenotype (12). The MHC
isoforms have traditionally been the subject of investigations defining phenotypic
alterations in muscle (13). This derives from the fact that myosin is an essential
component of the contractile system and that variations in the myosin structure
may underlie differences in muscle contractile properties. Mature smooth muscle
primarily expresses the smooth muscle MHC isoforms and to minor extent
non-muscle isoforms (11,14). The smooth muscle isoforms are 204 (SMI) and
200 (SM2) kDa, are derived from a single gene through alternative splicing, and
differ in their non-helical carboxyterminal tail region (15,16). There are at least
two non-muscle MHC isoforms, 200 (MHC-B) and 196 (MHC-A) kDa, which
are products of two distinct genes (17). While the former are expressed exclusively
in smooth muscle cells, the non-muscle isoforms are expressed in all cell types and
are involved in actin-based motile functions such as cell locomotion and division
(18). Expression of these 4 MHC isoforms is developmentally regulated in a tissue
specific manner. For example, during development, MHC-B is the predominant
200 kDa protein in vascular smooth muscle, reflecting incomplete maturation,
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and is replaced by SM2 (11,19). In fetal sheep, SMI is co-expressed with MHC-B
in vascular smooth muscle throughout most of gestation; SM2 expression occurs
late in gestation and postnatally and is associated with a reciprocal decline in
MHC-B (20,21). In contrast, the ovine bladder expresses abundant SMI and SM2
with little MHC-B at midgestation (21), demonstrating in the developing ovine
fetus that these maturational processes are tissue specific. This has not been char-
acterized in the ovine myometrium.
The sheep, because of its long gestation, the size of the fetus, and the ability to
alter the hormonal milieu while studying physiological responses m wvo, has been
extensively used to study the physiology of pregnancy (22-24) and the fetus (25).
Importantly, significant quantities of smooth muscle tissue can be obtained from
both fetal and neonatal animals to perform extensive studies of smooth muscle
maturation (20,21,26). Therefore, we sought to characterize the normal
ontogeny of contractile protein expression in myometrium from fetal and
neonatal sheep. In particular, we focused on the patterns of expression of the
major contractile proteins: actin, myosin and the MHC isoforms. We also
describe for the first time the effect that having been pregnant has on the expres-
sion of these proteins in ovine uterine smooth muscle. We hypothesized that there
is progressive cellular differentiation and smooth muscle maturation that begins
before birth, and that pregnancy has additional effects on uterine smooth muscle
phenorype.
METHODS
Female fetal (72-140d gestation, n=19; term 145d), postnatal (ld-3mon, n=21),
and parous noncycling adult (n=9) sheep were euthanized by rapid intravenous
injection of pentobarbital sodium (50 mg/kg) to the mother or neonate via the
external jugular vein. Ewes in the adult group were 14-30d postpartum with suck-
ling lambs. The uterus was quickly removed in block, and generous segments from
the uterine body were placed into iced phosphate buffed solution containing (in
mM): 137.0 NaCl, 2.7 KC1, 10 ^ H P C M , 1.76 KH2PO4, 0.1% diethyl
pyrocarbonate, pH 7.4. The adventitia and uterine epithelium were removed
using sharp dissection. Strips of myometrium were cut, blotted with a cotton swab
to remove excess water and capillary blood, frozen in liquid nitrogen, and stored
at -80°C until studied. Additional segments were obtained for contraction studies
and transported within 30min to another laboratory to measure forces as
described below. These studies were approved by the Institutional Review Board
for Animal Research at UT Southwestern Medical Center at Dallas.
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Profe/w tfwa/ys/s <z«d contends ** A
Samples of frozen tissue (10-20 mg) were weighed and homogenized in 40
volumes of sodium dodecyl sulfate (SDS) buffer as previously reported
(20,21,24,27). Homogenates were divided into two aliquots. One was subjected
to centrifugation at 10,000 x g for 2min, and the supernatant was removed to
determine the soluble or cellular protein in each sample. The other sample was not
centrifuged and was used to determine the total homogenate protein content,
which includes both soluble and insoluble protein, predominantly extracellular
matrix. Aliquots of both samples were analyzed for protein contents by BCA
reagent (Pierce, Rockford, III.). Bromophenol blue and 2-mercaptoethanol were
added to aliquots of the supernatant, and 20-40 ug of soluble protein were then
subjected to SDS-polyacrylamide gel electrophoresis (PAGE) using 3-20% and
4% polyacrylamide mini-gels to determine the contents of total actin and MHC
and the relative amounts of MHC-isoforms, respectively. Gels contained molec-
ular mass standards to confirm relative mobility (Bio-Rad, Hercules, CA) and
were subjected to electrophoresis at 200 V until the dye front reached the bottom
of the gel. Gels were stained with Coomassie brilliant blue overnight and appro-
priately destained to remove background staining. The fractions of Coomassie
blue-stained protein accounted for by actin and myosin in 3-20% gels and MHC
isoforms in 4% gels (Fig 1) were estimated by scanning laser densitometry (Model
2202/2220, LKB Instruments, Inc., Stockholm, Sweden). Lanes were scanned in
duplicate. Differences between measurements were <5%, and values for each
band were averaged. The fraction of stained protein accounted for by actin and
MHC was converted to micrograms knowing the amount of protein loaded for
each sample. Values are expressed as |ig/mg of wet weight.
Western
Since the 200 kDa MHC may consist of SM2, MHC-B or both, it was necessary to
perform western analysis to separate these MHC isoforms. Tissue extracts were
subjected to SDS-PAGE in 4% polyacrylamide mini-gels. Proteins were
electrophoretically transferred to nitrocellulose paper at 80 mA overnight. Blots
were incubated overnight with antisera to SM2 (1:4000) and MHC-B (1:20,000),
which were raised in this laboratory against synthetic peptides specific to each
isoform and characterized as described previously (20,21,26). Purified bovine
brain MHC-B was used as a standard and was the gift of Dr. Barbara Barylko.
Following 2h incubation with goat anti-rabbit IgG conjugated with horseradish
peroxidase (1:15,000), immunoreactive protein was visualized by chemilu-
minescence (ECL Amersham).
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Figure 1. Representative examples of 3-20% (A) and 4% (B) polyacryl-
amide mini-gels stained with Coomassie brilliant blue and then destained
to permit scanning laser densitometry (C). The gradient gel (A) demon-
strates the separation of protein in a homogenate of myometrium (Myo)
obtained from an adult ewe 38d postpartum. Myosin heavy chain (MHC;
-200 kDa) comigrates with MHC in the high molecular weight (HMW)
markers. The actin band is found at -42 kDa, migrating at a position
similar to ovalbumin (45 kDa) in both HMW and low molecular weight
(LMW) standards. The 4% gel (B) demonstrates the presence of filamin
(280 kDa) as the uppermost band and the myosin heavy chain isoforms a
pair of bands at 204 and 200 kDa as noted by the molecular marker
containing purified skeletal MHC. Densitometric scans (C) of MHC
isoforms in 4% gels were used to obtain relative amounts of 204 and 200
kDa bands in myometrial samples.
Data were analyzed using polynomial regression analysis with protein contents
(y-axis) versus gestational age in days (x-axis) to obtain estimates for significance
of fit to functions indicating non-zero slope (Sigma Stat 1.0). To further assess
changes during development animals were divided into 7 groups: fetal at <100d
(n=5), 101-130d (n=7) and 131-145d (n=7) gestation, and postnatal at l-7d
(n=6), 8-2Id (n=5), 22-30d (n=3) and >85d (n=4). Significance between groups
was assessed by one-way analysis of variance (ANOVA) with Newman-Keuls
correction for multiple comparisons to determine when in development signifi-
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cant changes may have occurred. Nonpaired t-test was used where appropriate.
Grouped data are reported as means ± SEM. Significance was taken as p=0.05.
RESULTS . : 1 . ., ']'""'• ,; 1
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Both total and soluble protein contents rose in parallel and proportionately
throughout development (Fig 2), values gradually increasing from 37+6 and 31±7
(ig/mg wet weight, respectively, at <100d gestation to 71±4 and 65±2 |ig/mg wet
weight, respectively, by lmon postnatal (P=0.001, R=0.53 and P=0.003,
R=0.59). Values were relatively unchanged at 85d postnatal, averaging 67±2 and
61±4 (ig/mg wet weight. Since the rise in total and soluble protein was propor-
tionate, the soluble:total protein ratio was ~0.84 until lmon postnatal when it
rose slightly to 0.91.
w am/ myostw fceat^' cfc<w'« cowtenfs
Actin and MHC contents in uterine smooth muscle also rose progressively during
development (Fig 3). Actin contents increased nearly 12-fold from 1.6±0.4 u.g/mg
wet weight at <100d gestation to 19±2 lmon after birth (P=0.002, R=0.56).
Values were similar at 3-4mon postnatal. When actin contents in myometrium
from nonparous ewes at 3-4mon were compared with those in parous noncycling
ewes, levels had increased 2-fold from 12+2 to 24+2 ug/mg wet weight (P=0.003),
respectively. MHC contents followed a similar pattern during development, but
rose only ~4-fold between <100d gestation and lmon postnatal (Fig 3), increasing
from 0.8±0.2 to 2.9+0.2 (ig/rng wet weight (P<0.001, R=0.62). Unlike actin, a
significant transition was seen between lOOd gestation and term, at which time
MHC contents rose 2.5-fold (P=0.01, ANOVA). Also in contrast to that seen with
actin, there was no significant change in MHC contents associated with parity,
i.e., levels were 3.3±0.3 and 3.6±0.4 ug/mg wet weight in myometrium from
nonparous and parous ewes, respectively. Since the rise in myosin was not propor-
tionate with that of actin, the actin:myosin ratio, which was -3 before birth,
increased to ~6 at lmon postnatal, resembling that seen at 3-4mon postnatal and
in the parous adult.
Myosm fceat7 cfcaiw iso/bmis
MHC isoforms separated by electrophoresis in gels containing 4% polyacryla-
mide yielded two protein species at relative mobilities of 204 and 200 kDa (Fig 1).
No species of lower mobility (196 kDa) were observed, possibly reflecting the care
to remove capillary blood prior to freezing. The relative amounts of the 204 and
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200 kDa bands were quantified by scanning densitometry and expressed as
percent of total MHC. The absolute content was then determined as the product
of the measured total myosin content and the percent mass of each isoform. Identi-
fication of MHC isoforms within the 200 kDa species was performed by Western
analysis.
The predominant MHC in myometrium from mid-gestation fetal sheep
(<100d) was the 200 kDa species, which accounted for 77±8% of total MHC (Fig
4). The relative amount of the 200 kDa protein declined rapidly during the latter
third of pregnancy and in the immediate postnatal period, accounting for only
25±2% of total myosin by lmon and 3-4mon postnatal (P<0.001, R=0.87). In
contrast, the relative amount of the 204 kDa isoform rose in a reciprocal manner
(P<0.001, R=0.87), increasing from 23±8% at <100d gestation to 75+2% at
3-4mon after birth (Fig 4). Significant differences in the relative amounts of each
isoform were evident at <100d and >101d gestation (P<0.001, ANOVA). In
parous noncycling ewes the relative distribution was significantly different
(P<0.001). The 204 and 200 kDa species accounted for 49.9±2.9 and 46.6±2.9%
of total MHC, respectively. Thus the 204:200 kDa ratio was -0.3 at mid-
gestation, 3.3 at lmon postnatal, and -1.0 after pregnancy.
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The tissue contents of these MHC species (|ig/mg of wet weight) were calculated
and resulted in a pattern distinctly different from that seen for the relative
amounts shown in Figure 4. Whereas the contents of the 204 kDa isoform
increased 7-fold from 0.3±0.1 at <100d gestation to 2.4±0.2 |ig/mg of wet weight
by 3-4mon postnatal (P<0.001, R=0.65), the 200 kDa contents remained quite
low and did not differ in the fetus, newborn and nonparous 3-4mon sheep, aver-
aging 0.7 ±0.1 ug/mg of wet weight (Fig 5). As with the relative distribution of
MHC, parity modified the contents of the 204 and 200 kDa proteins, reflecting
the change in distribution. The contents of the 204 kDa protein fell 28% to
1.73±0.12 Lig/mg of wet weight (P=0.01), while the 200 kDa species rose 149% to
1.74+0.25 (P=0.02); thus the contents of the two isoforms became equal.
Since the 200 kDa species may consist of SM2, MHC-B or both MHC
isoforms, we determined the developmental dependence of expression of each by
immunoblotting with antibodies specific for SM2 and MHC-B (20,21,26). Each
immunoblot was loaded with three standards: sheep platelets as a marker for
MHC-A (196 kDa), purified bovine brain myosin as a marker for MHC-B, and
adult ovine myometrium as a marker for SM2. Although we never detected a
protein species at 196 kDa, it is possible that ovine MHC-A may migrate at a
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Figure 4. Change in the relative distribution of 204
and 200 kDa MHC isoforms in myometrium during
ovine development. Values were derived by calcu-
lating the percent of total staining for MHC (200+204
kDa) comprised by each isoform on 4% SDS-PAGE.
Polynomial regression curves are shown as solid lines
through the data to distinguish the two groups. The
open triangles represent the relative amount of 204
kDa protein and the solid triangles the 200 kDa
protein.
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different position. We were unable to rule out the presence of MHC-A in these
samples because the antibodies against human platelet MHC-A peptide used in
these studies did not cross-react with sheep platelet protein and polyclonal anti-
bodies against human platelet MHC-A showed cross-reactivity with bovine
MHC-B. The specificities of anti-MHC-B and anti-SM2 are illustrated on repre-
sentative immunoblots shown in Figure 6. Although the myometrial contents of
total 200 kDa MHC were unchanged during development (Fig 5), the isoform
distribution changed dramatically (Fig 6). MHC-B was abundant at mid-
gestation and declined after birth, such that it was not seen in adult tissues. In
contrast, SM2, which was barely detected prior to 130d gestation, demonstrated
an increased expression, which was most dramatic after birth. SM2 expression
was robust in myometrium from the parous adult ewe and accounted for all of the
200 kDa protein (data not shown).
ONTOGENY OF UTERINE SMOOTH MUSCLE PROTEINS 91
Term
7
_ 6
II;
Figure 5. Changes in tissue contents of
the 204 and 200 kDa MHC isoforms
(ug/mg of wet weight) in myometrium
during ovine development. Graph prop-
erties are as described in Figure 2. '••;
en
re «-
1
r
6
S
4
3
2
1
0
I
I
-
-
60 100 140
Fetal age
(days)
• < • • . • • • . • • • ;
*, , , ^ * ? ,
36 76 115
Postnatal age
(days)
165
SM2
StdStdStd 88 93 110 133 140 2d 17d 30d 3m 4m
Pit B8 SM2 FWal PostnaW
MHCB
Std Std Std 88 93 110 133 140 2d 17d 30d 3m 4m
PH BB SM2 Fatal Postnatal
Figure 6. Representative immunoblots illus-
trating the changes in expression of the 200
kDa MHC isoforms, SM2 and MHC-B, in
myometrium during ovine development.
Standards (Std) included sheep platelet
lysate (Pit), MHC-B purified from bovine
brain (BB), and adult myometrial homoge-
nate (SM2). Numbers represents days
following conception (term -145d). Sepa-
rating gels were loaded with sufficient
protein to yield 200 ng of total MHC per
sample, as calculated from MHC contents
assessed above.
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Cytodifferentiation of the developing uterus occurs postnatally in most mammals
(1,7-9). However, existing evidence suggests that in the human and ovine species
progressive cellular differentiation and maturation begins »'« wtero (3,4,10). By
midgestation both species demonstrate histologic and ultrastructural evidence of
a definitive smooth muscle layer followed by continuing maturational changes
(4,10). Unlike smaller mammals, maturation of ovine uterine smooth muscle has
not been defined biochemically, and functional correlates are unclear. In the
present study we characterized the biochemical changes that occur in ovine
myometrium between 70d gestation and 4mon postnatal. We observed that
smooth muscle differentiation occurs early in the midtrimester, reflected by
expression of the 204 kDa smooth muscle MHC (SMI), that progressive increases
occur in the contents of contractile proteins early in the last third of pregnancy,
and that myometrial maturation begins /« Mtero and continues during the first
month postnatal as evidenced by decreases in the contents of non-muscle MHC-B
and increases in the smooth muscle MHC, SM2. Furthermore, we demonstrate
that having been pregnant further modifies the distribution and contents of
myometrial contractile proteins. These data, therefore, provide new insights into
the developmental and maturational changes that occur in ovine myometrium.
Although uterine morphogenesis occurs iw wfero in all species, cellular differ-
entiation and maturation are predominately postnatal events in most mammals
studied (1,4,7,8). In contrast, Konishiet al (10) and Wiley et al (3), using histologic
methods, reported definite cellular differentiation at 20-26wks in the human
female fetus and 90-1 OOd gestation in sheep, and that maturation continues there-
after. Utilizing biochemical markers, we have demonstrated that cellular differen-
tiation of the ovine myometrium occurs as early as 70d postconception, as
evidenced by the presence of the 204 kDa smooth muscle MHC. Of the proteins
characteristic of smooth muscle cells, the smooth muscle MHCs are considered
definitive markers of the smooth muscle cell lineage (11,12). Thus the presence of
SMI and its increasing expression during fetal development clearly supports the
conclusion that ovine myometrial differentiation begins /« Htero, probably before
70d gestation, and that maturational events proceed throughout the remainder of
gestation.
The development of smooth muscle tissues is associated with a continuum of
committed but not fully differentiated smooth muscle phenotypes (11), which has
been demonstrated in vascular smooth muscle from several species (21,28,29).
Evidence is now presented to support this in ovine myometrial development.
Although myometrium expressed SMI early in gestation, it represented <25% of
total MHC; thus the 200 kDa species was the predominant MHC. Unlike the
developing mouse and swine (28,30), the 200 kDa MHC consisted entirely of the
non-muscle isoform, MHC-B. The co-expression of MHC-B with SMI has been
considered evidence of a "synthetic" or immature smooth muscle phenotype,
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which has the potential to divide and grow (11). The subsequent decline in
myometrial MHC-B late in ovine gestation and during the immediate postnatal
period, reflects continuing maturational changes and the development of a mature
or "contractile" smooth muscle phenotype by the end of the first month postnatal.
This pattern resembles that seen in the developing ovine aorta, but differs from the
ovine fetal bladder, in which there is minimal MHC-B expression early in gesta-
tion, but abundant SM1 and SM2 (21). It is notable that this was associated with a
fully functional bladder in the midtrimester whereas aortic function was greatly
attenuated (21). Similar differences in maturational rates between the
myometrium and bladder occur histologically in the human fetus (10) and in the
mouse postnatally (28). These data, therefore, provide evidence in large mammals
that maturation is tissue specific in visceral as well as vascular smooth muscle, and
that the timing is species specific.
In addition to the developmentally regulated changes in myometrial MHC
isoforms, the tissue contents of total and soluble protein also increased progres-
sively. The principle connective tissue components in smooth muscle tissues are
collagen and elastin, which are insoluble in SDS homogenizing buffer due to
extensive covalent cross-linking that occurs following secretion of these matrix
proteins (31). Protein remaining after sedimentation of homogenates is predomi-
nantly cellular. Consistent with this, we found the lowest ratios of soluble to total
protein in the elastic ovine aorta: 0.61, followed by the bladder: 0.82, and
myometrium: 0.90 (21). Although the contents of cellular protein in myometrium
increased during development, total protein rose proportionally, and their ratio
remained 0.8 to 0.9. Thus changes in the cellular and matrix components of the
myometrium occur in parallel during fetal maturation, resembling that observed
in the ovine bladder (21). The rise in protein contents was paralleled by even
greater increases in actin and myosin contents, values increasing 12- and 4-fold,
respectively, by lmon postnatal. Thus at term gestation there was evidence not
only of a progressive change in smooth muscle phenotype, depicted by the rise in
smooth muscle MHC and fall in the non-muscle isoform, but also of a specific
increase in the cellular contents of contractile proteins, further demonstrating a
continuum of maturation within the myometrium. This too is consistent with
observations in vascular smooth muscle (21,28,29). In preliminary studies, these
biochemical changes were associated with spontaneous myometrial activity and
the capacity of myometrial strips from term sheep to contract, although both were
attenuated compared with adult tissues. Thus while fetal myometrium has no
known physiologic role, the contractile apparatus appears to be functional, even
though SM2 expression was minimal and MHC-B continued to be expressed.
Additional studies are needed to address the relationship between protein expres-
sion and smooth muscle function.
In previous studies the biochemical and histologic changes occurring in
myometrial development were compared with that in nonpregnant, nonparous
adults (3,7-9,28,30). It was unclear, however, if additional changes occurred after
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having experienced a pregnancy. In the rabbit, parity increases myometrial cell
size and contents of myofilaments, organelles and dense bodies (9). In the rat (32)
and monkey (33) the SM1:SM2 ratio is similar in nongravid and gravid animals;
postpartum parous animals were not studied. In the ewe, pregnancy increases
myometrial actin and myosin contents, which decrease in the postpartum period
(24); but there was no comparison with nonparous animals. In each species,
however, pregnancy is associated with increased capacity for myometrial contrac-
tions. We now report that having been pregnant increases actin but not myosin
contents when compared to nonparous animals, and that the relative and absolute
contents of SM1 and SM2 also change. That is, the SMI :SM2 ratio falls from 3.3
at 3-4mon postnatal, a value similar to that in the nonparous mouse and rat
(28,30), to -1 in the parous ewe, primarily reflecting an increase in the cellular
contents of SM2. Thus pregnancy further alters uterine smooth muscle protein
expression which could modify myometrial function at the time of parturition in
subsequent pregnancies.
In the present report we have characterized the developmental changes that
occur in the uterine smooth muscle of a large mammal, the ewe, demonstrating
that the ontogeny of ovine myometrium resembles that seen in the human, but
differs from that occurring in smaller mammals. This difference between large and
small mammals is largely one of timing, with the latter occurring postnatally. The
data also demonstrate that differentiation of ovine myometrium begins early in
the middle third of gestation and continues throughout the fetal and neonatal
periods, with substantial changes occurring prior to and soon after birth. More-
over, there is tissue/organ specific maturation in both visceral and vascular
smooth muscle (11,20,21,26,28), suggesting that local factors, including mechan-
ical stresses, may be involved in the determination of protein expression and the
rate of cellular maturation. Additional studies are needed to determine the molec-
ular mechanisms that regulate these varying rates of development and to better
characterize the functional changes that occur.
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Maturation of cytoskeletal proteins in vascular and visceral smooth muscle
was studied during ovine fetal and postnatal development by measures of
actin-binding proteins caldesmon, calponin and filamin, and the intermediate
filament proteins. Proteins were assessed by SDS-PAGE and western analysis
with specific antibodies in abdominal aorta and bladder from fetal (72-145d
gestation; terml45±5d), postnatal (ld-3mon) and adult sheep. In aorta, both
h-caldesmon and calponin increased progressively from about 20% adult
values at lOOd gestation to adult values at 1-4 weeks after birth (p=0.001,
ANOVA). In contrast, in bladder smooth muscle both caldesmon and calponin
were expressed at values comparable to adult as early as lOOd gestation. Simi-
larly, filamin increased in aorta from 0.9±0.3 |ig/mg wet weight to 1.9±0.2 at
3mon (p=0.003, ANOVA), whereas it was unchanged in bladder, averaging
2.4±0.2 ug/mg wet weight. A different pattern was seen with the intermediate
filament proteins which were unchanged in aorta (1.7±0.1 |xg/mg), but in
bladder increased from 2.0+0.5 at lOOd gestation to 6.0±1.0 by 140d gesta-
tion, remaining stable thereafter (p=0.002, ANOVA). The expression of
cytoskeletal proteins in developing smooth muscle is coordinately regulated.
However, expression of the actin-binding proteins appears to be regulated in a
manner distinct from the intermediate filament proteins. These results also
demonstrate that smooth muscle of the bladder matures during prenatal devel-
opment, well before birth, whereas that of the aorta matures more slowly over
the entire course of the prenatal and postnatal periods.
Keywords: caldesmon, calponin, filamin, intermediate filaments
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Smooth muscle plays an important role in the function of several organ systems
essential to normal growth, development and adaptation of the fetus and
newborn. In the cardiovascular system smooth muscle modulates arterial pres-
sure and mediates vascular responses to numerous endogenous stimuli, where in
the urinary tract it is essential for normal bladder filling and micturition. Delinea-
tion of the normal course of vascular and visceral smooth muscle maturation will
be critical to understanding congenital defects occurring in vascular and visceral
development (1,2). We previously showed in the sheep that aortic smooth muscle
attains a mature contractile phenotype only after birth, whereas bladder smooth
muscle matures early during prenatal development (3,4). Contractile phenotype
was assessed by comparing the temporal changes in actin, myosin heavy chain
(MHC), and total protein contents, as well as stress generating capacity during the
last trimester of gestation and during postnatal development. In those studies,
aortic actin contents were found to rise gradually between 115d gestation (term is
145d) and 3mon postnatal, attaining adult values in the postnatal period. In
contrast, bladder actin contents rose abruptly after lOOd gestation, achieving
adult values well before term. Accompanying changes in actin-binding proteins
that may have an effect on contractile capacity have not been described.
Actin is a highly abundant cytoskeletal protein involved in a wide variety of
cellular structures, the geometry and stability of which depend upon actin-binding
proteins. In mature smooth muscle tissues, actin, in the form of thin filaments,
supports myosin-dependent force development and shortening. In adult animals,
the actin-binding proteins calponin and h-caldesmon are expressed exclusively in
smooth muscle and are implicated in the regulation of actomyosin interactions
and therefore contraction (5,6,7,8). Calponin and h-caldesmon have been local-
ized in myosin-containing contractile domains of smooth muscle cells (9,10). The
onset of expression of these proteins has been shown in vascular smooth muscle to
occur after detection of the smooth muscle isoform a-actin, but before smooth
muscle isoforms of myosin heavy chain (MHC), thus they have served as markers
of smooth muscle maturation during development and after birth
(1,2,11,12,13,14). The onset of h-caldesmon expression is also accompanied by
down-regulation of the non-muscle isoform 1-caldesmon (1,2,12,13,14). In addi-
tion to supporting contraction, actin also provides structural stability in
cytoskeletal regions of mature smooth muscle cells where thin filaments are
cross-linked into a three-dimensional network by the potent actin-binding protein
filamin (9,15,16). Filamin, although not smooth-muscle specific, is found in
abundance in smooth muscle and in proliferating tissues (17,18). The
cytoskeleton of smooth muscle also contains structural filaments of the interme-
diate (lOnm) class that are composed primarily of desmin and vimentin
(19,20,21,22), with desmin being a muscle-specific form (19). Immuno-
histochemical staining of avian embryos suggests that both filamin and desmin
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expression precede that of calponin and h-caldesmon in vascular, as well as
visceral, smooth muscles during development (11).
In the present study, we tested the hypothesis that the actin-binding proteins
h-caldesmon, calponin and filamin are expressed in coordination with actin
during development in aorta and bladder smooth muscles. In addition, alterations
in amounts of the cytoskeletal intermediate filament proteins were assessed. We
found in aorta that the actin-binding proteins h-caldesmon, calponin and filamin
did not achieve adult values until after birth, consistent with the gradual matura-
tion observed for actin and MHC contents, as well as isoforms of MHC in this
tissue. In contrast, in bladder muscle the contents of all three actin-binding
proteins at any time during maturation were not different from those in adult
tissues, consistent with early maturation in this tissue. Interestingly, the opposite
pattern was observed for intermediate filament proteins, indicating that thin and
intermediate classes of filamentous cytoskeletal proteins are subject to different
regulatory schemes during growth and maturation. -
METHODS
T/sswe
Female fetal (72-140d of gestation, n=19; term -145d), postnatal (l-120d, n=25)
and adult (n=5) sheep were killed by rapid intravenous injection of pentobarbital
sodium (50mg/kg) to the mother or neonate via the external jugular vein.
Segments of abdominal aorta and bladder were quickly removed from all animals
and placed into iced physiological buffed solution containing (in mM): 137.0
NaCl, 2.7 KC1, 10 Na2HPC>4, 1.76 KH2PO4. 0.1% diethyl pyrocarbonate, pH
7.4. Aortic endothelium and adventitia and bladder epithelium were removed
with a soft cotton swab and sharp dissection, respectively. Strips of tissue were
cut, gently blotted to remove excess water and capillary blood, frozen in liquid
nitrogen, and stored at -80?C until studied. Protocols for the use of sheep were
approved by the Institutional Animal Care and Reseach Advisory Committee.
Prote/w awfl/ys/s awJ contends
Sodium dodecyl sulfate (SDS) homogenates were prepared from 10-20mg
samples of frozen tissue as previously described (4). Homogenates were subjected
to centrifugation at 10,000 x g for 2min, and the supernatant was removed to
determine the soluble or cellular protein in each sample. Protein concentration
was determined by BCA reagent (Pierce, Rockford, IL). Aliquots of the
supernatant containing bromphenol blue and 2-mercaptoethanol were subjected
to SDS-PAGE in 3-20% polyacrylamide gels to determine the contents of filamin
and desmin. For each tissue, gels were loaded with 20 |ig of soluble protein and a
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molecular weight standard and subjected to electrophoresis at 200V until the dye
front ran off the bottom of the gel. Gels were stained with Coomassie Brilliant Blue
overnight and appropriately destained to remove background staining (Fig 1 A).
Gels were scanned, each lane in duplicate, with a laser densitometer (LKB Instru-
ments, Inc., Stockholm, Sweden) to estimate the fraction of total stained protein
occupied by filamin (-280 kDa) and intermediate filament (IF) proteins (53-55
kDa). The band corresponding to filamin was previously identified by
immunoblotting (23). IF proteins in smooth muscle can be estimated from whole
muscle preparations owing to their relative abundance (20,21). In addition, we
confirmed by immunoblotting that this band contained desmin in both aortic and
bladder samples. Values for each band were averaged, and the fractional content
of filamin or IF protein was converted to micrograms using the total protein quan-
tified by BCA reagent. Values are expressed as ug/mg of tissue wet weight.
Western
To examine expression of h- and 1-caldesmon and calponin, tissue extracts (2.5 u.g
of soluble protein) were subjected to electrophoresis in 3-20% gradient
polyacrylamide gels. Proteins were electrophoretically transferred to nitrocellu-
lose paper at 100V for lh. The membranes were cut according to molecular
weight markers. The top half of these blots, molecular weights >47 kDa, were
incubated overnight with antiserum against caldesmon (1:10,000) that detects
both h-caldesmon (-140 kDa) and 1-caldesmon (-80 kDa) isoforms (24). The
bottom half of the membranes, molecular weights <47 kDa, were incubated over-
night with an antibody (Sigma; 1:10,000) against calponin (-34 kDa). The
following morning blots were incubated with horseradish peroxidase-conjugated
goat anti-rabbit IgG or goat anti-mouse IgG (1:15,000) respectively. Immuno-
reactive protein was then visualized by enhanced chemiluminescence (ECL,
Amersham). Each immunoblot contained samples obtained across development
plus tissue from adult ewes (Fig 1B). Blots were subjected to densitometric analysis
and values normalized to the adult sample for both proteins.
STATISTICAL ANALYSIS
Grouped data are reported as means ± SEM. Groups were defined as follows: 1)
midgestation (< 100d;n=6), 2) the fetal period of rapid growth preceding increases
in estrogen and cortisol (101-130d;n=8), 3) preparation for parturition
(131-145d gestation;n=6), 4) adaptation immediately following birth (l-7d;n=8),
5) postnatal adaptation (8d - lmon;n=7), 6) 3-4mon or late postnatal (n=9), and
7) adult. Groups contained from 6-9 samples. Data were analyzed using Student's
t-test and one-way analysis of variance (ANOVA) with Newman-Keuls correc-
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Figure 1. Representative images of Coomassie Blue-stained 3-20% polyacrylamide gel (A) and
immunoblots (B). A. 20 ug of soluble protein were loaded in each lane. Positions of filamin,
myosin heavy chain (MHC), intermediate filament (IF) protein and actin bands are indicated.
B. 2.5 ug of soluble protein from aortic tissues collected at the indicated times during develop-
ment were loaded in each lane. Proteins were detected with specific antibodies as described in
Methods. • . ; - • • . : : • , . • " • : < • • : • • : • • " ' • • .• •. • •.
tion for multiple comparisons. Significance was taken as p=0.05. Values
presented are means ± SEM.
RESULTS
CaWeswow a«d ai/powm
The h-caldesmon contents in aortic smooth muscle demonstrated a progressive
rise during development (p=0.001, ANOVA), increasing 4-fold from lOOd to
term, and achieving adult values by lmon postnatal (Fig IB and 2). Although
1-caldesmon was present throughout development, its content was unchanged
(data not shown) and did not differ from that in adult. Thus the ratio of 1- to
h-caldesmon fell from 11.8 to 0.75 at lmon postnatal. In the bladder a different
pattern was observed. Both h-caldesmon and 1-caldesmon were present during
development; but expression of h-caldesmon at < 1 OOd gestation resembled that in
adult tissues (Fig 2). Furthermore, the ratio of 1- to h-caldesmon in bladder was
unchanged and averaged 0.28.
Calponin was present before lOOd gestation in aortic smooth muscle (Fig IB)
and progressively increased from 22±8 % of adult expression to 74±10% at
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Figure 2. Patterns of h-caldesmon and calponin expression in aorta and
bladder smooth muscle during ovine development. Values were derived from
densitometric scans of immunoblots and normalized to those in adult tissues,
represented as 100%. Groups are as follows: lOOd, <100d gestation; 115d,
101-130d gestation; 140d, 131-145d gestation; Iwk, 0-7d postnatal; lm,
8d-lm postnatal; 3-4m, 3-4m postnatal; and adult. Values are means ± SEM.
Different letters denote significant differences at p<0.05 among age groups by
ANOVA, whereas groups not significantly different from each other are
denoted by the same letters.
3-4mon postnatal, at which time expression was not different from that in adult
tissues (p=0.0007, ANOVA) (Fig 2). In contrast, calponin expression in bladder
smooth muscle did not change significantly during development, always resem-
bling that in adult bladder smooth muscle.
F/7aw/« and / /i/amewf protew contents
Quantitative analysis of filamin protein contents in aortic and bladder smooth
muscle was carried out by densitometric analysis of tissue protein subjected to
electrophoresis in 3-20% gradient gels (Fig 1). Although the content of filamin in
aortic smooth muscle increased from 0.9±0.1 ug/mg wet weight at <100d gesta-
tion to 1.9±0.2 M-g/mg wet weight at 3-4mon postnatal (ANOVA, p=0.003), this
was not significant until lmon after birth (Fig 3). Filamin contents in bladder
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Figure 3. Filamin contents (|ig/mg of wet weight) in aorta and bladder smooth
muscle during ovine development. Values were derived from densitometric scans
of 3-20% polyacrylamide gels. Groups are as defined in Fig. 2. Values are means
± SEM. Different letters denote significant differences at p<0.05 among age
groups by ANOVA, whereas groups not significantly different from each other are
denoted by the same letters.
smooth muscle showed high variation, thus, unlike the aorta, no change was
detected when the entire period was analysed (Fig 3). Values averaged 2.4±0.2
ug/mg wet weight.
In contrast to the pattern of gradual increases of actin-binding proteins
observed in the aorta, contents of the intermediate filament proteins were
unchanged in aorta throughout the period of development studied (Fig 3), values
averaging 1.7±0.1 ^g/mg wet weight. As observed for most smooth muscle
proteins (3), the bladder tissue contents of intermediate filament proteins
exceeded that in aorta during late fetal and postnatal development. Furthermore,
there was a rapid, progressive increase in IF protein contents during the last month
of pregnancy, contents increasing -3-fold from 2.0+0.5 to 6.0±1.0 |ig/mg wet
weight by 140d gestation (ANOVA, p=0.002), following which values remained
stable (Fig 3).
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Results of the present study are consistent with our previous observations that
smooth muscle of the bladder matures during prenatal development and well
before term gestation, whereas aortic smooth muscle matures more slowly over
the entire course of the prenatal and postnatal periods (3,4). The smooth
muscle-specific, actin-binding proteins h-caldesmon and calponin, as well as the
more ubiquitous filamin, were present in amounts comparable to adult in bladder
tissues from all stages studied, indicating that this tissue exhibits early "acceler-
ated" maturation. In contrast, each of these proteins in aortic smooth muscle
exhibited a gradual rise during fetal and postnatal development with tissues from
midgestation containing a fraction the amount in adult. This pattern is very
similar to that seen with total actin contents in the aorta (3). We hypothesized that
the actin-binding proteins, h-caldesmon, calponin and filamin, would be ex-
pressed in coordination with actin. Whereas this appears to hold for aorta, a
different conclusion is drawn for bladder, where content of these proteins remains
stable while actin and myosin heavy chain contents increase about 3-fold during
the late stages of fetal development (3). In bladder, this is associated with a six-fold
increase in stress generating capacity (3). As both caldesmon and calponin inhibit
the actin-activated MgATPase activity of myosin (5,6,7,8), we might speculate
that the apparent decrease in their proportion to total actin may contribute to
enhanced stress generation previously observed.
In addition to the gradual and sequential onset of various smooth muscle-
specific protein markers, smooth muscle development is also accompanied by the
down-regulation of non-muscle isoforms that are expressed in immature muscle
(1,2). For example, in the ovine aorta the non-muscle MHC-B was gradually
replaced by the smooth muscle SM-2; however, no MHC-B was found in bladder
muscle as early as 70d gestation (3). This pattern has also been observed for the
alternatively spliced isoforms of caldesmon in chick (12) and human (13,14)
smooth muscle development, where expression of h-caldesmon increases progres-
sively and 1-caldesmon decreases to minor levels. Surprisingly, 1-caldesmon is
present in sheep aortic as well as bladder smooth muscle throughout develop-
ment. Because of the significant increase in h-caldesmon in aortic muscle, there
was a substantial decline in the proportion of total caldesmon comprised of the
1-form with maturity. In contrast, bladder muscle retained a lower, but constant
proportion of 1-caldesmon throughout. We speculate that any changes in the
proportions of these isoforms, as well as the contents of calponin and filamin in
bladder precede mid-gestation and may coincide with the period (60-90d gesta-
tion) when bladder function is increasing (25,26).
The smooth muscle cytoskeleton is a three-dimensional array of filaments
(actin-containing thin filaments, desmin- and/or vimentin-containing interme-
diate filaments, and tubulin-containing microtubules) that provides structural
integrity and functional support for many cellular processes. Thin and interme-
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diate filaments comprise the bulk of the cytoskeleton in mature smooth muscle
and have been proposed to exist in subcellular domains referred to as "contrac-
tile," including a-actin, myosin, caldesmon and calponin, and "cytoskeletal,"
including desmin/vimentin, p*-actin, filamin, and calponin (9,10). A comparison
of patterns of intermediate filament protein expression with those previously
obtained for actin (3) shows that these two classes of protein increase in parallel in
the ovine bladder, reaching adult values during the last third of fetal development.
In contrast, actin contents in aorta increase gradually during fetal and post-natal
development, while IF protein remains unchanged. These results may suggest that
the development of subcellular domains exhibits tissue specificity, and that these
domains need not augment in parallel. In adult sheep, bladder IF protein content
exceeds that in aorta, while there is no difference in actin content, resulting in a
ratio of IF protein to actin of 0.30 in bladder and 0.13 in aorta. A lower ratio of IF
protein to actin in vascular compared to visceral muscle has also been observed in
adult porcine tissues (21), again indicating tissue-specific regulation of cyto-
skeletal domains. Further investigations will be required to evaluate whether there
is a conversion of IF proteins from vimentin to desmin during ovine smooth
muscle maturation as reported for smooth muscle types in the rat lung (27), and
whether these developmental patterns differ between vascular and visceral muscle
(22).
We can conclude from this study that the onset of expression of actin-binding
proteins h-caldesmon, calponin and filamin, as well as the intermediate filament
proteins occurs before mid-gestation in the sheep. However, the patterns of
expression show marked tissue specificity when comparing aorta and bladder
smooth muscle. By using a large animal model, quantitative changes in cyto-
skeletal proteins could be studied over a prolonged period of time not only during
neonatal life, but also in fetal and adult stages of life. These results also provide a
continuum with other studies done in our laboratory using the same animals as
used in our contractile protein studies and functional contraction studies (3,4).
The advanced maturation and growth of bladder smooth muscle as compared to
aortic points to the early demands for function of the bladder (25,26) and rela-
tively minor roles of aortic and systemic arterial contraction in fetal cardiovas-
cular homeostasis (28,29). Both environmental factors and intracellular elements
involved in regulating the coordinated patterns of protein expression in devel-
oping smooth muscles remain to be explored.
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Large left to right shunts in infants with congenital heart disease may result in
development of PAH. Prenatal placement of aortopulmonary shunts in fetal
sheep mimics this condition, resulting in increased PBF and PAH by 4wks
postnatal. Whereas cardiovascular changes and pulmonary artery (PA)
morphology are described in PAH, alterations of SM contractile proteins and
cell phenotype are unknown. To address this, we obtained 3rd-4th generations
of PA and femoral arteries from twin lambs at 1 mon postnatal, one with an
aortopulmonary shunt (n=8) and the other without (n=7). We measured SM
contents of total and soluble protein, actin, myosin, desmin, filamin and
MHC-isoforms using SDS-PAGE with 3-20% and 4% polyacrylamide gels.
200 kDa MHC-isoforms, calponin and caldesmon were measured by Western
immunoblott analysis. While PA total protein was unaltered, soluble protein
and soluble to total protein ratios in PAH were decreased 35% and 25%,
respectively. Although PA actin was unchanged, MHC contents were
decreased 51% (6.54±0.81 to 3.23±0.43 ug/mg of wet weight, p<0.01) and
actin to myosin ratios were increased 58% in PAH. PAH also caused 204 and
200 kDa MHC-isoforms to decrease from 4.64±0.56 and 1.90±0.25 to
2.18±0.29 and 1.05+0.15 Ug/mg of wet weight, respectively. Interfilament
protein (Desmin) contents in PAH were unchanged, whereas filamin content
was 63% lower. By Western immunoblot, PAH was associated with a 96%
greater expression of MHC-B; SM2 was unaltered. Although calponin and
caldesmon expressions were unaffected, the 1- to h-caldesmon ratio was 55%
greater in PAH, suggesting predominance of the immature isoform. In
contrast, femoral artery SM protein contents were unaffected by PAH.
Increases in PBF in postnatal sheep with aortopulmonary shunts result in
persistence of an immature phenotype in PA SM, which may reflect the
ongoing SM growth associated with vascular remodeling and possibly vascular
dysfunction.
Key words: pulmonary hypertension, smooth muscle
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The hemodynamic adaptation to extrauterine life (abruptly decreased PAP and
PVR) results in remodeling of pulmonary vasculature to establish gas exchange
(1,2). Any disturbance of this process leads to abnormal pathology changes in
pulmonary vascular bed and eventually life threatening disease (3). While congen-
ital heart disease with left to right shunts results in pulmonary vascular disease in
infancy and childhood (4,5), PPHN causes a high mortality in the early neonatal
period. To understand the mechanisms of these diseases, several experimental
models were developed. In utero placement of aortopulmonary shunts in fetal
sheep which resulted in a tremendous increase in PBF and slowly decreased PVR
mimicked congenital heart disease in human infants such as ventricular septal
defect, atrioventricular canal or truncus arteriosus (6). The other adaptive failure,
PPHN, was represented by the models of chronic hypoxia in newborn calves at
high altitude (7,8) and prenatal ductus ligation in fetal lambs (9-11), where PAP
and PVR remained high postnatally while PBF diminished (9,10). Although the
hemodynamic findings were not completely uniform, the link between these
models was the persistence of high PAP resulting in consistent pathologic features,
which included an abnormal extension of SM into small or intra-acinar arteries
and an increased percent medial thickness in PA (6-8,12,13).
Since PA SM is substantially involved in PAH, the SM proteins are most likely
affected during this abnormal vascular remodeling. SM is composed of a contrac-
tile domain and a cytoskeletal channel (14). In the contractile domain, actin and
myosin are the major proteins in the thin and thick filament, respectively. Myosin
is a large protein made of 6 polypeptide chains, 2 identical myosin heavy chains
(MHC) and two pairs of light chains (15). MHC in human aorta has, at least, 3
major isoforms: SM, (204 kDa), SM2 (200 kDa), and MHC-B (200 kDa) (16).
While SM 1 and SM2 are considered to be mature isoforms expressed as a contrac-
tile phenotype, MHC-B is a nonmuscle isoform associated with a synthetic pheno-
type conducting a role in SM cell growth and cell division (16-19). The
expressions of these SM proteins are developmentally regulated. While SMI is
expressed throughout development, SM2 is upregulated during late fetal and
postnatal period. In contrast, MHC-B is the predominant MHCI in the fetus and
its level decreases significantly after birth (16-19).
The cytoskeletal channel consists of many specific proteins providing support
for the contractile machinery (14,9,20). The interfilament proteins and filamin
can be electrophoretically separated by SDS-PAGE on a gradient gel and are also
reported to be increased in a parallel manner with the progressive development of
the contractile domain (19-21).
Calponin and caldesmon are actin-binding proteins in the contractile domain
involved in the regulation of SM contraction through an inhibitory effect on
ATPase activity of the actomyosin complex (19,22). The proportions of
caldesmon variants are altered during development. 1-Caldesmon, the low molec-
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ular weight form of caldesmon (70 kDa), is detected in early fetal life and is
replaced by h-caldesmon the high molecular weight form (150 kDa), which
increases in mature SM (19,22-24). Calponin and h-caldesmon are considered
markers of SM maturation (24).
In PAH, the regulation of SM protein production and differentiation are
changed. We reported that in prenatal ductal ligation, the expression of
MHC-isoforms is altered. There is an increase in MHC-B and decrease in SM2
(25). The conversion of MHC-isoforms from a contractile to synthetic phenotype
was presumably associated with a decreased capacity for stress generation (25).
Regarding the integrated molecular structures in SM cells, other regulatory and
cytoskeletal proteins may be affected in concert with alterations of MHCI in
response to PAH. Although the alterations of SM proteins and MHC-isoforms are
previously described, they have not been performed in this model of congenital
heart disease. Therefore, we studied smooth muscle alterations in PA to determine
the expression of contractile and cytoskeletal proteins in newborn lambs with
high PAP and PBF.
METHODS
Eight pregnant mixed-breed western ewes with twin gestations were operated
upon at the University of California, San Francisco at ~140d of gestation under
sterile condition with epidural anesthesia and intravenous sedation. One twin
fetus (n=8) was partially exposed through a hysterotomy, and a thoracotomy was
performed as previously described (6). Briefly, the arterial truck and the main
pulmonary artery were dissected, and an aortotomy and pulmonary arteriotomy
were performed. Between these two arteries, an 8.0-mm expanded
polytetrafluoroethylene vascular graft (2 mm length) (Gore-tex; W.L. Gore and
Assoc) was placed to provide an aortopulmonary shunt. The other twin (n=7)
served as a control and was not operated upon. The thoracotomy incision was
closed, and the fetus was returned into the uterus. Amniotic fluid was replaced by
warm saline before closure of the uterine incision. Postoperatively, the ewes
recovered and the fetuses were allowed to deliver spontaneously at term.
Following delivery, lambs were maintained in a holding area until one month of
age when they were killed with lethal doses of intravenous pentobarbital sodium,
and tissue was collected. These protocols were approved by the Committee on
Animal Research of the University of California, San Francisco.
The lungs were removed in block and third and fourth generations of PA and
femoral arteries were collected. Adventitia and adjacent lung tissue were removed
by blunt dissection and endothelium was removed with a soft cotton swab. Strips
of arteries were cut, frozen in liquid nitrogen, and stored at -80°c until studied.
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SDS homogenates were prepared from 15-20 mg of frozen tissue and divided into
2 aliquots. One aliquot was centrifuged at 10,000xg for 2min, and the
supernatant was removed for determination of soluble or cellular protein and
subsequent gel electrophoresis. The other aliquot was not centrifuged and was
used to measure total homogenate protein (sum of cellular and extracellular frac-
tions). Total and soluble protein contents were analyzed using BCA reagent
(Pierce, Rockford, IL); bovine serum albumin (BSA) (Pierce, Rockford, IL) was
used to construct a standard curve between the optical density and protein
content. Another aliquot of the supernatant was mixed with 0.2% bromphenol
blue and Bis-mercaptoethanol, and 20 |ig of soluble protein was subjected to
SDS-PAGE, using 3-20% polyacrylamide gels, to determine the contents of actin,
MHC, desmin, and filamin. Electrophoresis was run at 200 V until the dye front
ran of the gel. Each gel also contained lanes for high and low molecular weight
standards (Biorad laboratories, Hercules, CA) to determine the molecular mass of
protein bands. Gels were stained overnight with Coomassie Brilliant Blue, and
background staining was then removed with appropriate destaining solutions.
The protein bands were scanned in duplicate with a laser densitometer (model
2202, LKB instruments, Inc., Stockholm, Sweden) and the absorbance recorded
by a 2220 LKB recording integrator. The amounts of each protein were calculated
by using the average values of the areas under peaks. These values were converted
to micrograms using the total protein measured by BCA reagent in each sample
and were expressed as ug/mg of wet weight. The amounts of 204 kDa and 200 kDa
MHC-isoforms were determined by loading one microgram of myosin on 4%
polyacrylamide gels.
Two peptides of 9 amino acids were synthesized based on the specific amino acid
sequence of the 200 kDa MHC from bovine brain (MHC-B) and adult rabbit
aorta (SM2) and then conjugated to tuberculin purified protein derivative. The
antisera were produced by immunization these proteins in rabbits by the Animal
Resources Center, UT Southwestern Medical Center. The specificity of these anti-
sera was illustrated by Western immunoblot using purified bovine myosin (gift of
Barbara Barylko) for MHC-B and adult myometrium for SM2 (26).
The purified caldesmon was prepared from chicken gizzards and injected into
rabbits to produce the polyclonal anti-caldesmon by the Animal Resources
Center, UT Southwestern Medical Center (27).
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To determine the expression of 200 kDa MHC- isoforms, MHC-B and SM2,400
ng of myosin were loaded and separated on 4% polyacrylamide gels. Each gel also
contained 200 ng of purified bovine brain myosin and adult myometrium myosin
to serve as controls for MHC-B and SM2, respectively. Proteins were transferred
by electrophoresis to nitrocellulose paper at 100 V for 1.5h. Blots were blocked in
the buffer contained powdered milk (0.3% wt/vol) for 2h and incubated over-
night with blocking buffer containing antisera (1:10,000) against MHC-B or anti-
sera (1:4,000) against SM2. Two percent of sodium azide (1:2,000) was added to
prevent bacterial contamination. The blots then were incubated with goat
anti-rabbit IgG conjugated with horseradish peroxidase (HRP) (1:15,000) (Bio-
Rad Laboratories, Hercules, CA) for 1 h 45min. Afterwards, the blots were placed
in Enhanced Chemiluminescence (ECL) for 1 min and exposed on ECL film in a
dark room. The bands of MHC-B and SM2 were visualized on the films and were
scanned on an Arcus II scanner (Agfa) with software, FotoLook 95 V.2.08-
Standalone. The relative volumes of these bands were determined by densitometry
using a Molecular analyst software V. 1.3 (Bio-Rad laboratories, Hercules, CA).
Calponin and caldesmon expression was determined by loading 2 and 0.5 ug
of soluble protein, respectively, on 3-20% polyacrylamide gels, and separated by
SDS-PAGE. Western immunoblots were performed for each protein as described
above. The blots for calponin were blocked and incubated with monoclonal anti-
sera (1:10,000) against calponin prepared from human uterus smooth muscle
extract (Sigma, St Louis, MO) and then with goat anti-mouse IgG-HRP conjugate
(1:15,000 Bio-Rad Laboratories, Hercules, CA). The blots for caldesmon were
incubated with antisera (1:20,000) against caldesmon and goat anti-rabbit
IgG-HRP conjugate (1:15,000). The relative volumes of calponin and 1- and
h-caldesmon were determined by densitometry using methods described above.
STATISTICS
The data from each study group was analyzed by descriptive statistics and
presented as the mean ± SEM. The unpaired student t-test was used to determine
the differences between groups. Significance was observed at p=0.05.
RESULTS
Pw/mo/wry /4/Yery Proton, /4 crm d»c/ Myosm
Total protein contents were not significantly different between control and
shunted animals (Fig 1A). In contrast, contents of soluble protein were 35% less
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(p=0.039) in PA from shunted lambs (Fig 1B). Therefore, the ratio of soluble to total
protein was 25% less (p=0.015) in shunted animals, 0.49+0.05 versus 0.65±0.03.
Actin contents in PA from shunted animals were decreased 23% compared to
the other twin, but this difference was not significant (Fig 2A). In contrast, the
myosin content was 51 % less in the lambs with PAH (p=0.002) (Fig 2B), resulting
in an increase of 58% in the actin to myosin ratio in the shunted lambs, 3.08±0.21
versus 1.95+0.14 (p=0.001).
Pw/woMtfry Arrery MHC-zso/brms Jte
In concert with the decreased contents of total MHC in PA from shunted animals,
there was a 53 % (p=0.001) and 45% (p=0.010) decrease in the content of the 204
and 200 kDa isoforms respectively (Fig 3A and 3B). Since the 200 kDa MHC-
isoform represented as MHC-B or SM2 in PA SM, they were separated by Western
immunoblot analysis using specific antisera (see methods), and the differences
were analyzed by densitometric analysis. Although there was no difference
detected in the SM2 expression, MHC-B expression was 96% greater in PA from
shunted animals (Fig 4).
A f "'
Pw/mowtfry Artery J«ter/i7<zmeMf protein <z«<i H U R
These proteins represent the cytoskeletal domain of SM cells and can be measured
on 3-20% polyacrylamide gels with SDS-PAGE. Interfilament protein contents
were 38% less in PA from shunted lambs with PAH, however, this was not signifi-
cant (Fig 5A). The filamin content, however, was significantly less in PA from
shunted animals, 0.75±0.15 versus 2.02±0.39 pg/mg of wet weight in the other
twin (p=0.007) (Fig 5B).
P«/wo«ary Artery Gz/pomn an</ G?/<fesmon
Although the protein expression of total calponin and caldesmon was unaffected
by PAH, the ratio of low and high molecular weight caldesmon was significantly
greater in PA of animals with PAH 0.53±0.07 versus 0.34±0.03 (p=0.044) (Fig 6).
Therefore, there is a predominance of the low molecular weight isoform.
Femora/ Arteries Protezw Express/ow
There was no significant difference in SM protein expression in femoral arteries of
shunted and control lambs (data not shown), except for a modest decrease in the
calponin expression (p=0.05) in shunted animals.
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Figure 1. Contents of total (A) and soluble (B) protein in pulmonary arteries from control and
shunted postnatal sheep. Values are means ± SEM. *p=0.039.
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Figure 2. Contents of actin (A) and myosin (B) in pulmonary arteries from control and shunted
postnatal sheep. Values are means ± SEM. *p=0.002.
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Figure 3. Contents of 204 (A) and 200 (B) kDa myosin heavy chain isoforms in pulmonary
arteries from control and shunted postnatal sheep.Values are means ± SEM. *p=0.001,
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Figure 4. A representative Western immuno-
blot demonstrating the expression of the 200
kDa MHC-B in pulmonary arteries from
control (Lane 1 to 5) and shunted (Lane
6-11) postnatal sheep. Lane 12 is purified
bovine brain myosin. The results of volu-
metric densitometry (sec methods) are shows
in the lower half of the figure from control
(n=7) and shunted (n=8) animals. Values are
means ± SEM. *p=0.017.
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Figure 5. Contents of desmin (A) and filamin (B) in pulmonary arteries from control and
shunted postnatal sheep. Values are means ± SEM. *p=0.007.
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Figure 6. The ratio of 1- to h-caldesmon in
pulmonary arteries from control and shunted
postnatal sheep. Values are means ± SEM.
•p=0.044.
DISCUSSION
The abnormal hemodynamic status in 1 month old lambs with systemic-to-
pulmonary communications results in structural changes, which possibly repre-
sented an early adaptation of congenital heart disease with high PBF in human
infants (3-6). The increase in percent medial thickness in PA from shunted lambs
was similar to that observed in other animal reflecting the postnatal response of
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PA to persistently high PAP models (7,8,12,13). Although this morphological
change was previously described as a result of SM cells hyperplasia and/or hyper-
trophy in response to hemodynamic stress (28,29), in this study, we demonstrated
a decrease in intracellular SM protein content in shunted lambs, while the total
protein contents remains unchanged.
The arterial media is organized into lamellar units called musculo-elastic fascicles,
which consist of elastic fibers forming layers between aligned SM cells and
collagen fibers (30). In developing vessels, this connective tissue is produced by
SM cells and consequently constitutes a significant mass of the pulmonary arterial
wall (1,2,31). Since newborns have a greater potential to produce extracellular
matrix (30,31), hypoxic newborn calves with PAH accelerate the deposition of
elastin and collagen in both adventitial and medial layers (7,8,33,34). Corre-
spondingly, in infants with pulmonary hypertensive heart disease, the proportion
of medial connective tissue to SM cells in the wall of small PA was greatest in the
youngest age group, 2-6 month old (32). The soluble protein contents in PA calcu-
lated per tissue wet weight were relatively decreased in shunted lambs when
extracellular matrix proteins were additionally increased.
The major cellular proteins in vascular SM capable of contractions, actin and
myosin, are affected in PAH. While actin was the only SM contractile protein
shown to be transiently increased in intra-acinar arteries from infants with pulmo-
nary hypertensive heart disease at 2 months of age (35), actin and myosin expres-
sion was inconsistently described to either increase (11) or to stay stabile in animal
models with PAH (25). In contrast, we demonstrate a decrease in both contractile
proteins in 1 month old sheep with aortopulmonary shunts. Since myosin
contents have decreased significantly more than actin content, the actin to myosin
ratio was subsequently increased. The variations of the SM protein expression are
probably due to the differences in experimental models, time and severity between
animal and human diseases.
We previously reported the unchanged myosin contents but converted
proportions of MHC-isoforms in prenatal ductus ligation model (25). In the
present study we observed significantly decreased amounts of 200 and 204 kDa
MHC-isoforms in a parallel pattern with the decreased myosin in shunted lambs,
although the proportions were not changed. Accordingly, we postulated that the
total myosin and also MHC-isoforms in PA SM declined in response to increased
PAP and possibly associated with SM functional changes.
In addition to MHC, the PA SM cytoskeletal channel, which normally
develops in parallel with the contractile domain (19-21), may be concurrently
involved in the abnormal remodeling process. Although they were not exclusively
studied, the alterations of SM cytoskeletal proteins were shown to be selective to
specific subpopulations and possibly time-dependent expression. While the
interfilament protein vimentin was transiently increased in infants with pulmo-
nary hypertensive heart disease during 2 to 8 month of age (35), PA SM prolifera-
tion in newborn calves with hypoxic PAH was shown to occur almost exclusively
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in metavinculin-negative SM subpopulation (36). We studied different SM
proteins and demonstrated an unchanged interfilament desmin content, but a
significant decrease in filamin content in shunted lambs versus control. SM
cytoskeletal protein is selectively affected in PAH and filamin protein expression
is decreased in concert with the contractile proteins, which altogether contributes
to the decrease of cellular protein contents in PA SM in animals with PAH.
200 kDa MHC is represented as two isoforms. While SM2 is a smooth muscle
isoform expressed in the mature contractile phenotype, MHC-B is an immature
isoform related to SM cell replication (16-19). In response to PAH, SM changes its
protein expression from a contractile to synthetic phenotype (31), which enhances
tissue growth and repair. On the other hand, the accelerated cell growth results in
thickening of arterial wall and a subsequent decrease in the diameter of vascular
lumen. The conversion of MHC-isoforms was consistently demonstrated in the
models of prenatal ductus ligation (11,25). While Belik showed an increased
percentage of unspecified nonmuscle MHC-isoform (11), Chapados established
an increased in MHC-B and a decrease in SMMHCI, (25). We found an increase in
MHC-B expression in PA SM from shunted lambs compared to control, while
SM2 did not differ. In this regard, we determined that the predominance of the
synthetic phenotype, MHC-B, enabled the PA SM to proliferate resulting in the
increased medial thickness in PA.
The regulatory proteins in SM contractile domain, calponin and caldesmon
are probably involved together with the alterations of the contractile proteins.
Opposite to normal development, we reported a significant increase of 1- to
h-caldesmon ratio in PA SM from shunted lambs with PAH, although the relative
amount of caldesmon and calponin are unaltered. Therefore, the conversion of
caldesmon corresponds with the alterations of MHC isoforms suggesting that the
immature isoforms in PA SM are significantly expressed in PAH. Since immature
isoforms are expressed as synthetic rather than the contractile phenotype, these
alterations of SM proteins may have a consequent effect on PA vascular functions.
The increase of SM immature isoforms in 2nd to 4th generations PA from
newborn lambs with PAH resulted in a decreased capacity of stress generation in
response to variant stimuli (11,25). This circumstantial evidence suggests that PA
SM is not responsible for the PA hyper-reactivity or increased vascular tone in
PAH. The reactivity of PA to vasoactive stimuli in infants with congenital heart
disease or PPHN may be modified by other factors. The increases of vasoconstric-
tors, endothelin-1 and thromboxane A2, but impairment of endothe-
lium-dependent PA relaxation have been reported in infants with PAH (37-40),
these vasoactive products might play a potential role in pulmonary vasoregulation
(37-42). In addition, the smaller PA distal to the 4th generation and pulmonary
veins might also conduct vasoconstriction and participate in maintaining vascular
tone in PAH.
Although the mechanism responsible for controlling vascular remodeling and
SM protein expression are unknown, there is some evidence that
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high-pressure-induced vascular injury may expose medial and adventitial cells to
peptide mitogens and differentiation factors (42,43). Subsequently, these factors
such as insulin-like growth factor 1 (IGF-1), transforming growth factor-pl
(TGF-p 1) may have an effect on vascular remodeling and alterations of the pheno-
type of SM cells (43-45).
Since femoral artery SM proteins, except calponin, did not differ between
shunted and control animals, it suggests a specificity for SM protein alterations in
response to PAH to pulmonary vasculature.
We conclude that in the animal model of congenital heart disease with high
PBF, SM proteins in PA are altered with vascular remodeling. At 1 month of age,
PA contractile and cytoskeletal SM proteins are selectively decreased in response
to high PAP. The PA SM proteins are changed to immature isoforms reflecting the
ongoing vascular growth and possibly attenuated contractile capability. The
mechanisms controlling this alterations and modifying vascular reactivity need
further investigation to be elucidated, which might have implications in treatment
strategies.
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General discussion
An understanding of the normal regulation of smooth muscle differentiation and
maturation is critical to our understanding of congenital defects in vascular and
visceral development, as well as vascular development in tumors or arterioscle-
rosis.
It has been emphasized by Owens (1) that there is a continuum of differenti-
ated phenotypes that exists between the committed, but undifferentiated smooth
muscle cell in one end of the spectrum and the contractile mature smooth muscle
cell on the other. Specific marker proteins are induced sequentially during differ-
entiation and are documented most extensively in vascular smooth muscle. The
expression of contractile proteins is developmentally regulated, and prior to birth
a synthetic smooth muscle phenotype is predominant in systemic vasculature
(2,3). During smooth muscle development it is important to determine which of
the smooth muscle cell phenotypes is being studied. Furthermore, marker proteins
and their cellular function are to be identified in smooth muscle. Their phenotypic
state of these marker proteins and their pattern of expression are to be character-
ized. The protein isoform expression patterns of the major contractile proteins
have been evaluated extensively as qualitative indices of maturation, although
quantitative increases in contractile proteins have received scant attention. There
are few studies available focusing on late fetal or postnatal maturation (4,5,6).
Defe/opwe«ta//y regM/ate<i confracfr'/e proteins
We examined vascular and visceral smooth muscle tissues from fetal and neonatal
sheep. Sheep have been used to study various aspects of fetal physiology (7,8,9).
The large size of the fetus permits instrumentation and studies in utero. The rela-
tively long duration of gestation, 145±5days, allows the study of specific time
points during development more easily than in smaller species like rodents, whose
gestation is ~20d (10,11). Moreover, the hormonal milieu or time of parturition
can be modified to study cardiovascular development in fetal sheep.
In the present studies we demonstrated that maturation of vascular and
visceral smooth muscle tissues, as assessed by increases in contractile protein
contents, occurs continuously from mid-gestation through the first month of life.
Distinct differences were observed between tissues, leading to the conclusion that
smooth muscle maturation is tissue specific. For example, bladder smooth muscle
matures far in advance of another visceral muscle, the myometrium, as well as the
126 CHAPTER 9
vascular smooth muscle in the aorta. The expression of contractile proteins during
development is carefully orchestrated, yet patterns of expression differ in a tissue
specific manner. , ,
Smoof/7 mwsc/e myos/w j'so/brm express/on
Smooth muscle replication plays a central role in the pathogenesis of atheroscle-
rosis (12). It has been demonstrated that non-muscle MHC-B isoform of myosin is
re-expressed in smooth muscle cells of neointimas. These cells express SMI, but
little SM2. This MHC isoform profile in the smooth muscle of neointimas suggests
a dedifferentiation of smooth muscle towards the embryonic phenotype and
involvement in the cellular mechanism of the development of atherosclerosis (12).
There is a marked contrast of MHC expression in neointimal and medial smooth
muscle cells.
The role of the different myosin isoforms remains unclear. SMI and SM2 are
clearly associated with a mature contractile phenotype, whereas MHC-B expres-
sion in smooth muscle is associated with growth either during development,
disease or in cell culture (12,13,14). Variation of the C-terminal of SM-myosin has
little effect on the ability of isolated myosin to translocate actin in vitro motility
assays (15); however, studies in permeabilized fibers suggest that the unique
nonhelical tail region of SMI may modulate contractility through an interaction
with adjacent myosin molecules in the thick filament (16). Others have suggested
that SM1 and SM2 may have different effects on the filament stability and thereby
stress generation (17). While different smooth muscle tissues exhibit character-
istic ratios of SM 1 and SM2, a distinct population of cells can exist within a tissue
(18,19). The ultimate effect of cellular heterogeneity remains to be determined.
Non-muscle myosin exhibits different patterns of staining in tissues and isolated
cells, suggesting that they serve different functions (20,21). These and other
results favor the notion that expression of non-muscle myosin in smooth muscle
supports proliferation and other non-contractile functions during development
(22). Our finding that little or no MHC-B is expressed in bladder muscle during
fetal maturation may indicate that this muscle has a fully expanded population of
smooth muscle cells at an early stage, as compared to aorta and myometrium. This
remains to be determined. The data do not explain how this tissue specificity is
regulated.
Ro/e o/prote/MS a«d sfresses
We also examined the possibility that early maturation of bladder protein expres-
sion would be associated with early onset of contractile capacity. Developmental
increases in contractile content should be the foundation for increasing contractile
capacity during maturation (5,6). We compared contractions elicited by aorta,
bladder and myometrium from near-term fetal and adult sheep. Whereas fetal
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bladder exhibited spontaneous activity and gave robust contractile responses to
depolarization by KC1 and carbochol, aorta was refractory to all stimuli tested.
Fetal myometrium, on the other hand, exhibited spontaneous activity, but
contractile forces were a small fraction of those seen by maternal myometrium.
The results were consistent with the notion that bladder muscle growth and matu-
ration is initiated early in development and proceeds rapidly thereafter. The
pattern of myosin heavy chain species was very similar for aorta and myometrium,
yet strikingly different from those in the bladder. The advanced maturation and
growth of bladder smooth muscle as compared to aorta and myometrium prob-
ably reflects their functional differences during development. The uterus has no
known function until reproductive age is achieved, and the aorta is exposed to
relatively low arterial pressures until after birth (23). Thus the need for rapid
maturation changes in these tissues may be minimal. In contrast, the bladder is
functional early in development, excreting urine at a rate of -7-10 ml/kg-h as early
as 24wk gestation in the human (24,25,26). Since fetal growth is logarithmic after
lOOd, weight increases ~4-fold by term. The urine production also increases
~4ml/h to ~30ml/h. The intraluminal pressures and volumes must rise accord-
ingly, which may play a fundamental role in early maturation observed in bladder
smooth muscle.
The umbilical-placental circulation is crucial for fetal growth and well being.
After observing the differences in tissue maturation we decided to compare the
systemic circulation to the umbilical circulation, unique and only present during
fetal life. The responsiveness of the fetal peripheral vascular bed is known to be
less responsive to some vasoconstrictors, especially angiotensin II, compared to
the umbilical circulation (27,28,29). One explanation is that the contractile
protein composition and therefore the contractile capacity of vascular smooth
muscle in umbilical and systemic arteries differ. This observation is consistent
with the expression of the angiotensin receptor subtype expression in fetal sheep
(30).
Umbilical artery, like bladder, therefore demonstrates precocious maturation
not only in this early onset of contractility, but in achieving high (2-fold greater
than aorta or femoral artery) contents of actin and myosin in the absence of
MHC-B expression.
Significant differences exist between the umbilical and systemic responses to
vasoconstrictors (27,31,32).
OH
These findings raise provocative questions of the role of smooth muscle in cardio-
vascular function during development. Dawes suggested in 1968 that the
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umbilicoplacental bed might be important in regulating total peripheral resis-
tance, because it accounts for 40% of fetal cardiac output. Our group (28,30,31)
and others (27,33) reported this bed is very sensitive to angiotensin II. The major
response was seen in the umbilical artery and minimal responses were reported in
the fetal umbilical vein. The umbilical artery expresses the angiotensin 1 receptor
AT1R, which mediates contraction in the adult. In contrast, the fetal arteries
express only the angiotensin 2 receptor (AT2R) (28,30), whose function is not
known, but does not appear to be directly related to contraction (28). Ovine
umbilical responses exceed those of the systemic vasculature (27,28,32). The
mechanism for this is not known. It was noted that the hindlimb was less sensitive
to angiotensin II. Furthermore, there is evidence that there is autoregulation in the
hindlimb, which suggests peripheral responses to angiotensin might be due to the
myogenic response. This is supported by the results of Iwamoto and Rudolph
(27), who reported that relative to the umbilical circulation, the peripheral organ
and tissue blood flow was maintained during angiotensin II mediated increases in
arterial pressure. A possible explanation is that the contractile protein expression
in the fetal systemic vasculature is immature compared to the umbilical circula-
tion as is assessed by an abundance of nonmuscle MHC-B and decreased contents
of actin, myosin and smooth muscle MHC isoforms compared with the adult and
postnatal animal (2,3). When the umbilical and fetal systemic artery protein
expression was compared with adult vessels, only the umbilical artery resembles
the adult artery (34). If the AT2R is the predominant receptor in systemic arteries
prenatally and the expression of contractile proteins is immature, it is unclear how
the pressor responses are elicited. In the fetus, this may occur by constricting the
umbilicoplacental bed, which accounts for 40% of cardiac output.
We have shown that both fetal aorta and fetal femoral artery are refractory to
all stimuli, including KG; however, umbilical artery generated significant stress in
response to a number of agonist (34). The umbilical artery smooth muscle devel-
opment is precocious within the fetal vasculature. Advanced maturation has also
been described in the ductus arteriosus (20). The accelerated maturation of the
umbilical artery and ductus arteriosus appear to be unique to the fetal vasculature,
resembling adult vascular smooth muscle in both protein expression and capacity
to contract. Because the umbilical artery and ductus arteriosus constrict in term
infants soon after birth to redirect cardiac output, these differences may relate to
adaptive alterations necessary after birth.
Smooth muscle differentiation is a complex process that involves sequential
activation of genes encoding smooth muscle specific proteins. Whether this matu-
ration is determined by the embryonic origins of smooth muscle cells or by
paracrine, hormonal or mechanical factors remains to be investigated. This study
illustrates that maturation of the contractile protein phenotype is associated with
maturation of contractile function. Further studies will be required to determine
threshold conditions leading to contractile function, as well as specific queues
promoting maturation during development.
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Summary
During ovine development there are substantial tissue specific alterations that
occur in the expression and contents of several important contractile proteins and
the nonmuscle MHC isoforms in smooth muscle of a number of arteries and
visceral tissues. We studied animals before 80 days of gestation and after 3 months
postnatally, which had not been done before. Furthermore it had not been studied
in detail how the smooth muscle proteins are associated with the development of
smooth muscle cytoskeleton, e.g. a-actin, desmin, filamin and calponin, nor have
the other contractile protein expression been extensively studied. The contractile
proteins are believed to play an important role in the contractile properties of
smooth muscle cells and possibly their maturation, e.g. caldesmon, a-actin,
myosin, calponin, and myosin light chain kinase.
Chapter 1 is a review of the literature regarding the physiology of smooth
muscle contraction. In this chapter the contractile and cytoskeletal domain, the
contraction pathway, the regulatory factors and necessary stimulation of smooth
muscle contraction are discussed.
Chapter 2 describes the developmental aspect of smooth muscle as described
in the literature. It discusses the differentiation and maturation of smooth muscle.
Furthermore, it gives a review about markers of maturation. The major contrac-
tile and cytoskeletal proteins, which are studied in the rest of the thesis during
ovine development: actin, myosin, caldesmon, calponin, filamin, desmin, the
regulatory light chains and the enzyme myosin light chain kinase are reviewed.
Chapter 3 gives a short summary of the material and methods used in this
study.
Chapter 4 in this study the hypothesis is tested that smooth muscle maturation
is dictated by functional requirements. Amounts and patterns of actin and myosin
isoform expression as well as stress generating capacity are compared between the
bladder, and the aorta. The present results of this study indicate that bladder
smooth muscle undergoes accelerated maturation of the contractile phenotype
accompanied by the early onset of force development as compared to the vascular
smooth muscle of the aorta.
Chapter 5 in this study the hypothesis is tested that differences in vascular
responsiveness could reflect dissimilarities in the vascular smooth muscle pheno-
type during development. Actin, myosin, myosin isoforms, and active stresses
were compared in femoral and aortic smooth muscle in near-term and adult sheep
to external and internal umbilical arteries. We concluded that compared with the
umbilical and adult circulation, the fetal systemic vascular smooth muscle is
biochemically and functionally immature. Thus umbilical vascular smooth
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muscle demonstrates precocious maturation resembling adult vascular smooth
muscle in protein expression and function. '•' ' '
Chapter 6 this chapter focuses on the patterns of expression of the major
contractile proteins in the developing myometrium and the myometrium during
its reproductive cycle. Although no direct functional demand is known for the
fetal uterus, the smooth muscle development in the myometrium at the end of
gestation expresses the contractile phenotype and is capable of force generation,
unlike the systemic fetal vasculature.
Chapter 7 in this chapter the proteins examined are caldesmon, calponin,
desmin and filamin during an extended period of development. Distinct groups of
proteins appear to exist, whose expression is regulated differently. The results
indicate a time course of maturation in visceral smooth muscle, which is different
compared to vascular smooth muscle in both the cytoskeleton and contractile
domain.
Chapter 8 Large left to right shunts in fetuses with congenital heart disease
may result in development of pulmonary hypertension. In a sheep model of this
form of PAH the expression of contractile and cytoskeletal proteins is examined in
comparison with control animals. The conclusion of this study was that PAH
resulted in persistence of the immature phenotype in the pulmonary artery.
In conclusion the studies in this thesis show, as discussed in Chapter 9, that the
expression of contractile proteins during development are carefully orchestrated,
yet patterns of expression differ in a tissue specific manner. The fetal systemic
vascular smooth muscle in near-term fetal sheep is functionally immature as
assessed by MHC-B expression and attenuated stress generation. The umbilical
smooth muscle appears to be unique to the fetal vasculature, resembling adult
vascular smooth muscle in both protein expression and capacity to contract.
Bladder smooth muscle undergoes accelerated maturation compared to vascular
tissues during development. Maturation of the contractile phenotype is associated
with maturation of contractile function.
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Samenvatting ..,,.,„
Gedurende de foetale ontwikkeling gebeuren er substantiele weefsel specifieke
veranderingen in de expressie van de verschillende contractiele eiwitten in glad
spierweefsel van vaten en holle organen. Wij bestudeerden in dit proefschrift
schapen vanaf 80 dagen gestatie tot 3 maanden na de geboorte en volwassen
schapen. Het was niet bekend hoe de glad spierweefsel eiwitten zijn geassocieerd
met de ontwikkeling van het cytoskelet. Gekeken werd naar de rol van de eiwitten
actin, desmin, filamin en calponin. Tevens waren de eiwitten, die geassocieerd
worden met het contractile domein niet volledig onderzocht. Deze contractile
eiwitten spelen een belangrijke rol in de contractile eigenschappen van de glad
spierweefsel eel: actin, myosin, caldesmon, calponin en myosin light chain kinase.
Hoofdstuk 1 geeft een overzicht van de literatuur over de fysiologie van glad
spierweefsel contractiliteit. In dit hoofdstuk worden het contractiele domein en
het cytoskelet, de contractie pathway en de regulatie en stimulatie van glad spier-
weefsel besproken.
Hoofdstuk 2 beschrijft een literatuurstudie van de ontwikkeling van glad
spierweefsel. Differentiate en maturatie worden besproken. De belangrijkste
contractiele en cytoskelet eiwitten worden samengevat, te weten actin, myosin,
caldesmon, calponin, desmin, filamin, regulerende light chains en het enzym
myosin light chain kinase.
Hoofdstuk 3 geeft een korte samenvatting van de gebruikte materialen en
methoden.
Hoofdstuk 4 beschrijft de hypothese of glad spierweefsel maturatie samen-
gaat met functie. De hoeveelheid en expressie patronen van actin en myosin, als
ook het vermogen tot stress generatie worden vergeleken in twee weefsels: blaas en
aorta. De resultaten wijzen erop dat glad spierweefsel in de blaas een versnelde
maturatie ondergaat naar het contractiele fenotype, wat samengaat met een
vroege aanzet tot het vermogen tot krachtontwikkeling vergeleken met de aorta.
Hoofdstuk 5 licht de hypothese in deze studie toe, namelijk dat er verschil is in
vasculaire respons in verschillend vasculair glad spierweefsel tijdens foetale en
postnatale ontwikkeling. Actin, myosin, myosine isovormen en actieve stress
worden vergeleken in foetale aorta en arteria femoralis, externe en interne arteria
umbilicalis en volwassen aorta en arteria femoralis. Uit deze studie konden wij
concluderen, dat vergeleken met de umbilicale en volwassen circulatie, het foetale
vaatstelsel immatuur is, zowel biochemisch als functioned. De umbilicale circu-
latie lijkt in eiwit opmaak en functie op volwassen glad spierweefsel.
Hoofdstuk 6 beschrijft het patroon van contractiele eiwit expressie in het foetale
en neonatale myometrium en het myometrium tijdens de reproductieve cyclus.
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Ofschoon er geen functie bekend is voor de foetale uterus tijdens ontwikkeling,
heeft het glad spierweefsel aan het einde van gestatie het contactiele fenotype en is
in staat tot stress generatie. Dit in tegenstelling tot het systemische foetale vaat-
stelsel.
Hoofdstuk 7 bestudeert de eiwitten caldesmin, calponin, desmin en filamin
tijdens de ontwikkeling. Er lijken verscheidene groepen te bestaan, waarvan de
expressie verschillend wordt gereguleerd. De resultaten wijzen op een patroon van
maturatie van visceraal gladspierweefsel, wat anders is dan vasculair glad spier-
weefsel, zowel in het contractiele domein als in het cytoskelet.
Hoofdstuk 8 een grote links/rechts shunt in foetusen met een congenitale hart-
afwijking kan resulteren in pulmonale hypertensie. In het diermodel voor deze
vorm van pulmonale hypertensie wordt de expressie van contractiele eiwitten en
de eiwitten van het cytoskelet bestudeerd en vergeleken met controle dieren. De
conclusie was, dat deze vorm van pulmonale hypertensie resulteert in continue-
ring van het immature fenotype in de arteria pulmonalis.
Hoofdstuk 9 bevat de conclusie van de studies in dit proefschrift en de
discussie daaromtrent. De expressie van contractile eiwitten tijdens foetale
ontwikkeling is zorgvuldig georkestreerd en het patroon is anders in de diverse
bestudeerde weefsels. Het foetale systemische vaatstelsel is immatuur, wat blijkt
uit de expressie van MHC-B en het verlate vermogen tot stress generatie. Het
umbilicale systeem is uniek in het foetale vaatstelsel. Het is te vergelijken met het
volwassen vaatstelsel in eiwit expressie en het vermogen tot contractie. De blaas
ondergaat een versnelde, mogelijk aan functie gerelateerde maturatie tijdens de
foetale ontwikkeling. De maturatie van het contractile fenotype is geassocieerd
met contractile functie.
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